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Tumour	 angiogenesis	 is	 a	 hallmark	 of	 cancer.	 Focal	 adhesion	 kinase	
(FAK)	 is	 a	 non-receptor	 tyrosine	 kinase	 involved	 in	 endothelial	 cells	 (ECs)	
survival,	proliferation	and	migration.	FAK	has	several	tyrosine	phosphorylation	






angiogenesis	 (in	 sygeneic	 B16F0,	 CMT19T	 and	 LLC)	 but	 impaired	 B16F0	 and	
CMT19T	 tumour	 growth	 only,	 with	 increased	 tumour	 hypoxia.	 FAK-Y397F	
tumour	endothelium	is	not	perfusion,	leakage	or	vascular	maturation	defective.	
This	mutation	 affects	 VEGF-,	 PlGF-	 and	 bFGF-driven	 angiogenesis	 in	 vivo	 and	
VEGF+Ang2	administration	is	able	to	partially	rescue	this	phenotype	ex	vivo.		
In	contrast,	endothelial	FAK-Y861F	mutation	leads	to	an	initial	delay	in	




and	 bFGF-driven	 angiogenesis	 in	 vivo	 and	 ex	 vivo	 was	 not	 affected	 by	 the	
endothelial	 FAK-Y861F	mutation,	whereas	 increased	 in	vivo	 angiogenesis	was	
triggered	by	Ang2	administration.		
	 4	
Lastly,	 to	 understand	 whether	 cytokine	 profiles	 that	 might	 affect	
angiocrine	 signalling	 are	 affected	 differentially	 in	 FAK-Y397F	 vs	 FAK-Y861F	
endothelial	cells,	I	show	that	CCL1	and	CCL2	are	increased	in	FAK-Y397F	but	IL-
13,	 IL-1F3,	 CCL4,	 IL-1F1,	 CCL2	 and	 others	 are	 increased	 in	 FAK-Y861F	
endothelial	cells.	
	 Overall	my	data	indicates	that	endothelial-specific	FAK	mutations	on	two	
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In	 the	mouse,	 the	yolk	sac	vasculature	starts	 to	 form	at	embryonic	day	
(E)	6.5	when	haemangioblasts	derived	from	the	mesoderm	form	blood	islands.	
When	 exposed	 to	 basic	 Fibroblast	 Growth	 Factor	 (bFGF,	 also	 named	 FGF2),	
haemangioblasts	 give	 rise	 to	 angioblasts	 and	 hematopoietic	 stem	 cells	 (Choi,	
1998).	 Angioblasts	 then	 form	 endothelial	 cords	 establishing	 the	 primitive	
vascular	 plexus	 of	 the	 embryo	 (Conway,	 2001;	 Risau	 1997).	 From	 embryonic	
day	(E)	8.5,	sprouting	and	intussusceptive	angiogenesis	allow	the	formation	of	
the	mature	vascular	tree.	
The	 first	step	 in	sprouting	angiogenesis	 is	endothelial	cell	activation	by	
nitric	oxide	and	growth	factors	leading	to	the	destabilization	of	the	intercellular	
junctions	 in	 the	 existing	 endothelium	 (Gale	 and	 Yancopoulos,	 1999).	 As	 the	
extracellular	matrix	is	degraded,	endothelial	tip	cells	migrate	towards	to	growth	




and	 deposition	 and	 organization	 of	 vascular	 basement	 membrane	 help	 to	
maintain	 vascular	 integrity	 and	 diameter	 this	 controlling	 efficiency	 of	 blood	
flow.	
Intussusception	 angiogenesis	 does	 not	 require	 endothelial	 cell	






of	 endothelial	 cells	 lines	 the	 lumen	of	 all	 blood	 vessels,	 but	 the	proportion	of	
supporting	 vascular	 cells	 and	 the	 basement	 membrane	 composition	 varies	
between	the	different	vessel	types.	
The	 basement	 membrane	 is	 a	 specialized	 extracellular	 matrix	 that	
surrounds	 the	 basolateral	 side	 of	 the	 blood	 vessels.	 Vascular	 supporting	 cells	
and	endothelial	cells	contribute	to	the	basement	membrane	deposition	and	its	
composition	 varies	 from	 one	 organ	 to	 another,	 but	 is	 generally	 composed	 of	
collagen	 type	 IV,	 laminin,	 fibronectin,	 nidogen	 and	 heparin	 sulphate	
proteoglycan	perlecan	(Paulsson,	1992).	
Pericytes	 and	 vascular	 smooth	 muscle	 cells	 support	 and	 stabilize	 the	
vascular	 endothelium.	 Capillaries	 and	 postcapillary	 venules	 are	 coated	 with	
pericytes	that	extend	numerous	protrusions	through	the	basement	membrane	
to	 establish	 cell	 contact	 with	 endothelial	 cells.	 Vascular	 smooth	 muscle	 cells	
surround	 larger	 vessels	 such	 as	 arteries	 and	 veins	 (Gerhardt	 and	 Betsholtz,	
2003).	
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impacts	 pericyte	 coverage,	morphology	 and	molecular	 characteristics.	 Several	
markers	 are	 used	 to	 characterize	 pericytes	 such	 as	 smooth	 muscle	 α-actin	
(SMA),	 NG2	 proteoglycan,	 desmin,	 platelet-derived	 growth	 factor	 receptor	






Tumour	 angiogenesis	 occurs	 to	 supply	 the	 growing	 tumour	mass	with	
oxygen	and	nutrients,	as	well	as	to	help	evacuate	the	metabolic	wastes	resulting	
from	the	highly	proliferating	cancer	cells.	As	the	tumour	mass	grows,	the	tissue	
becomes	 hypoxic	 and	 tumour	 cells	 up-regulate	 the	Hypoxia	 Induced	 Factor-1	
(HIF-1)	 leading	 to	 the	 overexpression	 of	 pro-angiogenic	 growth	 factors,	
including	Vascular	Endothelial	Growth	Factor	(VEGF),	basic	Fibroblast	Growth	
Factor	 (bFGF),	 Platelet	 Derived	 Growth	 Factor	 (PDGF),	 Transforming	 Growth	
Factor	β	(TGFβ)	and	angiopoietins,	and	the	decrease	of	anti-angiogenic	signals,	
eg	 thrombospondin,	 interferon	 and	 cleaved	 products	 of	 plasminogen	
	 16	
(angiostatin)	 and	 collagen	 XVIII	 (endostatin)	 (Bergers	 and	 Benjamin,	 2003;	





Tumour	 angiogenesis	 results	 from	 an	 imbalance	 in	 the	 angiogenic	 signals	 in	




the	 angiogenic	 switch	 in	 several	 steps	 (Figure	 1.2).	 Firstly	 the	 cell	 junctions	
between	endothelial	cells	or	endothelial	and	mural	cells	are	loosened	(Gale	and	
Yancopoulos,	 1999).	 This	 process,	 alongside	 the	 degradation	 of	 extracellular	
matrix	by	metalloproteases,	allows	endothelial	cell	proliferation	and	directional	
migration	towards	the	hypoxic	site	and	tube	formation	(Weis,	2011;	Carmeliet,	
2000;	 Hua,	 2011).	 Proteolytic	 degradation	 of	 specific	 extracellular	 matrix	
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proteins	 can	 produce	 a	 variety	 of	 soluble	 fragments	 able	 to	 modulate	 the	
angiogenic	 response.	 For	 example,	 VEGF	 is	 normally	 tethered	 to	 the	
extracellular	matrix,	but	is	released	during	extracellular	matrix	degradation	to	
stimulate	 angiogenesis.	 Growth	 Factor	 signaling	 pathways,	 including	 the	
VEGF/VEGFR2	 signaling	 axis,	 crosstalk	 with	 integrin	 signaling	 pathways	 to	
allow	 the	 transition	 between	 an	 organized	 endothelial	 monolayer	 to	 a	






such	as	pericytes	and	smooth	muscle	 cells,	detach	 from	 the	vascular	wall	 and	
endothelial	 cells	 (in	 red)	 release	 proteases,	 which	 degrade	 their	 basement	
membrane	(1).	This	allows	them	to	migrate	 into	the	surrounding	 interstitium,	
resulting	in	the	formation	of	capillary	buds	and	sprouts	(2).	The	sprouts	further	
elongate	 through	 endothelial	 cell	 proliferation,	 branch	 and	 interconnect	 with	






cells	 and	 tip	 cells	 (Figure	 1.3).	 The	 stalk	 cells	 are	 thought	 to	 be	 highly	
proliferative,	 whereas	 the	 tip	 cells	 integrate	 signals	 from	 the	 surrounding	







The	quiescent	endothelium	 is	 formed	on	a	monolayer	of	endothelial	 cells	 that	






factors,	 such	 as	 platelet	 derived	 growth	 factor	 (PDGF),	 which	 attracts	
supporting	 cells,	 thus	 stabilizing	 the	 newly	 formed	 blood	 vessels.	 In	 spite	 of	
being	 continuously	 exposed	 to	 pro-angiogenic	 stimuli,	 a	 fraction	 of	 tumour	
blood	 vessels	 are	 covered	 with	 pericytes.	 Tumour	 vasculature,	 alongside	 the	
lymphatic	system,	 is	also	 involved	 in	metastatic	cancer	dissemination	(Hicklin	
and	Ellis,	2005).	
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The	FGFs	are	a	 fimily	of	22	growth	 factors	and	bFGF	was	 the	 first	pro-




1,	 -2,	 -3	and	 -4.	After	 ligand	binding,	 the	activated	FGFR	receptors	are	able	 to	
phosphorylate	 tyrosine	 residues	 from	 intracellular	 proteins	 belonging	 to	
signaling	 pathways	 amongst	 which	 RAS-MAPK,	 PI3K-AKT	 that	 are	 highly	
relevant	in	cancer	studies.	Moreover	bFGF	is	able	to	stimulate	angiogenesis	and	
was	 in	 fact	 the	 first	 pro-angiogenic	molecule	 to	 be	 identified.	Molecules	 from	
this	 family	 can	 be	 trapped	 in	 the	 extracellular	 matrix	 as	 a	 consequence	 of	
binding	 to	 Heparan	 Sulfate	 Proteoglycans,	 and	 can	 be	 later	 released	 in	 a	
coordinate	 manner	 due	 to	 heparanase	 activity.	 bFGF	 signaling	 can	 also	 to	






Placental	 Growth	 Factor	 (PlGF)	 and	 four	 other	 VEGF	 isoforms	 (A,	 B,	 C	
and	 D),	 encoded	 by	 different	 genes,	 have	 been	 identified	 and	 VEGF-A	 is	
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considered	to	be	a	major	regulator	of	blood	vessel	formation,	whereas	VEGF-C	
and	VEGF-D	are	specific	 to	 lymphatic	vessels	(Carmeliet,	2005).	VEGF-B	 is	 the	
most	abundant	VEGF	in	the	heart	and	was	shown	to	stimulate	coronary	vessel	
growth	and	arterialization.	
There	are	 three	spicing	 isoforms	of	VEGF-A	 in	mouse:	VEGF	121,	VEGF	
164	 and	 VEGF	 188.	 The	 loss	 of	 a	 single	 VEGF-A	 allele	 leads	 to	 embryonic	
lethality	at	(E)	11-12	due	to	lack	of	functional	vasculature	and	absence	of	blood	
islands	 (Carmeliet	 1996,	 Ferrara	 1996).	 Interestingly	 certain	 VEGF-A	 splicing	
isoforms	 have	 anti-angiogenic	 effects	 (Qui,	 2009).	 For	 example	 VEGF	 isoform	
resulting	from	differential	splicing	of	terminal	exon	8	is	anti-angiogenic	and	is	
widely	expressed	 in	healthy	 tissues;	however	 its	expression	 is	downregulated	
in	cancers.	
VEGF	 Receptors,	 VEGFR-1,	 VEGFR-2	 and	 VEGFR-3,	 belong	 to	 a	
superfamily	of	receptors	characterized	by	seven	extracellular	 immunoglobulin	
loops	 and	 an	 intracellular	 tyrosine	 kinase	 domain	 (Stuttfeld,	 2009).	 VEGFR-1	
and	 VEGFR-2	 are	 mainly	 expressed	 in	 endothelial	 cells,	 whereas	 VEGFR-3	
expression	 is	 restricted	 to	 lymphatic	 cells	 and	 some	 tumour	 endothelial	 cells	
(Laakkonen,	 2007).	 VEGFR-1	 is	 thought	 to	 negatively	 regulate	 angiogenesis,	
because	VEGFR-1	deficient	embryos	have	excessive	vascular	growth	and	die	in	
mid	gestation	(Fong,	1995).	Lack	of	vascular	development	in	VEGFR-2	deficient	
mice	 indicate	 that	 this	 receptor	 positively	 regulates	 angiogenesis	 (Shalaby,	
1995).	 In	 addition,	 VEGF	 stimulated	 signaling	 involves	 coreceptors	 such	 as	
heparin	 sulfate	 proteoglycan	 and	 neuropilin	 -1	 and	 -2	 (Cebe-Suarez,	 2006).	
Neuropilins	 were	 identified	 as	 Semaforin	 receptors	 for	 axonal	 guidance	 and	
later	shown	to	play	an	essential	role	in	development	of	vascular	and	lymphatic	
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Upon	 VEGF-A	 signaling	 VEGFR-2	 dimerisation	 triggers	 a	 signaling	
cascade	 involved	 in	 cell	 migration,	 survival	 and	 proliferation,	 important	
features	in	physiological	and	pathological	angiogenesis.		
Overexpression	of	VEGF	is	associated	with	tumour	progression	and	poor	
prognosis	 in	 gastric,	 colorectal,	 pancreatic,	 prostate,	 lung	 and	 breast	 cancers	




The	 anti-VEGF	 therapy	 is	 used	 to	 decrease	 the	 vascularisation	 of	 the	
tumour	mass,	leading	to	tumour	cell	death.	Two	strategies	are	used	to	interfere	
with	 the	 VEGF/VEGFR2	 signaling	 axis:	 neutralizing	 the	 VEGF	 molecule,	 thus	
interfering	with	 extracellular	 activation	 or	 using	 tyrosine	 kinase	 inhibitors	 to	
block	the	 intracellular	VEGFR2	signaling.	Bevacizumab,	that	has	demonstrated	




	 Preclinical	 trails	showed	that	anti-VEGF	treated	tumours	had	 increased	
FGF	and	FGFR	expression,	 suggesting	 that	 this	 signaling	 axis	 is	 the	 resistance	









Angiogenesis	 is	 dependent	 on	 the	 appropriate	 control	 of	 adhesive	
signals.	 Integrins	 are	 a	 family	 of	 heterodimeric	 transmembrane	 glycoproteins	
composed	 of	 non-covalently	 associated	 α	 and	 β	 subunits	 that	 mediate	 cell	
adhesion	with	the	extracellular	matrix	(Hynes,	2002b).	Mammalian	cells	have	8	
β	subunits	and	18	α	subunits	that	can	assemble	into	26	distinct	integrins.	There	
are	 four	 main	 groups	 of	 integrins:	 the	 RGD-integrin	 family	 (that	 binds	 to	 a	
arginine-glycine-aspartame	 consensus	 sequence),	 the	 collagen	 receptor	 family	
(that	 recognizes	 fibronectin	 and	 VCAM-1	 amongst	 others),	 the	 leucocyte-
specific	receptor	family	and	the	laminin	receptor	family.	The	combination	of	α	
and	 β	 subunits	 confers	 ligand	 specificity	 to	 one	 or	 more	 substrates.	 Some	










Endothelial	 cells	 express	8	 integrins	 that	mediate	 the	 interactions	with	
endothelial	 cell	 matrix	 components:	 α5β1,	 αvβ3	 and	 αvβ5	 bind	 to	 the	 RGD	
tripeptide	 motive	 of	 fibronectin,	 fibrinogen,	 vitronectin,	 etc;	 α3β1,	 α6β1	 and	
α6β4	primary	bind	to	 laminin;	and	α1β1	and	α2β1	have	affinity	 for	collagen	I	
and	 IV	 and	denatured	 collagen	 (Albelda,	 1989;	 Stromblad	and	Cheresh,	 1996;	
Hodivala-Dilke,	 2003).	 The	 upregulation	 of	 expression	 and	 activity	 of	 several	
integrins	has	been	reported	with	nascent	blood	vessels	(Hodivala-Dilke,	2003).	
αV	integrins	have	received	most	attention	in	this	field	and	have	been	associated	
with	 endothelial	 sprouts	 (Eliceiri	 and	 Cheresh,	 1999).	 During	 angiogenic	
remodeling,	endothelial	αVβ5	and	αvβ3	were	shown	to	be	upregulated	(Stupack	
and	 Cheresh,	 2002),	 but	 other	 integrins	 such	 as	 a5b1	 and	 a2b1	 are	 also	
upregulated.	 These	 observations	 together	 with	 the	 fact	 that	 integrins	 are	
transmembrane,	 made	 them	 ideal	 targets	 for	 anti-angiogenic	 therapy	
(Hodivala-Dilke,	2003;	Zhang,	2015).	






Angiopoietin	 receptor	 Tie-2	 physically	 interacts	 with	 α5β1	 leading	 to	
amplification	 of	 angiogenic	 signals	 (Cascone,	 2005).	 Integrin	 trafficking	 and	
internalization	 can	 modulate	 EGFR	 and	 VEGFR	 internalization	 and	 recycling	
(Caswell,	2008;	Reynolds,	2009).		
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Together	 all	 these	 functions	 of	 integrins	 mean	 that	 they	 are	 central	





often	 associated	with	 tumour	 growth	 and	 invasion.	Both	 genetic	 ablation	 and	
inhibition	studies	of	α5β1,	α1β1	and	α2β1	inhibit	angiogenesis,	indicating	that	
these	 integrins	 are	 pro-angiogenic	 (George,	 1993;	 Kim	 2000b,	 Pozzi	 2000;	
Senger,	1997;	Yang,	1993).	
Function	 blocking	 antibodies	 and	 small	 peptides	 targeted	 to	 αvβ3	 and	
αvβ5	 integrins	 have	 been	 shown	 to	 inhibit	 angiogenesis	 in	 tumours	 and	
retinopathy	models,	suggesting	that	these	integrins	are	pro-angiogenic	(Brooks,	
1994;	Brooks,	1995;	Friedlander,	1996;	Hammes,	1996).	However,	mice	lacking	
β3	 or	 β3	 and	 β5	 undergo	 normal	 developmental	 angiogenesis	 and	 have	
enhanced	 pathological	 angiogenesis	 (Hodivala-Dilke,	 1999;	 Reynolds,	 2002;	
Robinson,	2004).	These	observations	were	determined	to	be	a	consequence	of	
compensatory	 increased	expression	and	activity	of	VEGFR2	 (Reynolds,	 2002).	
Mice	 expressing	 a	 non-phosphorylatable	 β3	 did	 not	 show	 compensatory	
changes	 in	 VEGF	 signaling	 and	 presented	 with	 decreased	 angiogenesis,	





angiogenesis,	 suggesting	 that	 extended	 depletion	 of	 this	molecule	 leads	 to	 an	
escape	from	angiogenesis	inhibition	(Robinson,	2013).	
Integrins	 αvβ3	 and	 αvβ5	 promote	 two	 distinct	 cytokine-dependent	
pathways	 of	 angiogenesis.	 Angiogenesis	 induced	 by	 bFGF	 or	 TNF-α	 requires	
αvβ3	 integrin,	 whereas	 angiogenesis	 induced	 by	 VEGF	 or	 TGF-α	 is	 αvβ5	
dependent	 (Friedlander,	 1995).	 This	 is	 due	 to	 the	 ability	 of	 β3	 and	 β5	 to	






ubiquitous	 cytoplasmic	 tyrosine	 kinase	 highly	 phosphorylated	when	 localized	
at	focal	contacts	(Schaller,	1992).	
FAK	contains	a	N-terminal	FERM	domain,	a	central	kinase	domain,	three	
proline-rich	 domains	 and	 a	 C-terminal	 FAT	 domain	 (Girault,	 1999).	 Upon	
growth	 factor	 or	 integrin	 signaling	 FAK	 is	 autophosphorylated	 on	 Y397,	
creating	a	binding	site	for	Src	and	the	p85	subunit	of	PI3K.	This	is	followed	by	
subsequent	phosphorylations	at	Y576/Y577,	allowing	maximal	catalytic	activity	





FAK	 is	composed	of	a	FERM	domain,	a	kinase	domain	containing	 the	Y397,	 three	proline-rich	
domains	and	a	FAT	domain	where	 the	Y925	 is	 localized.	Upon	Growth	 factor	 and/or	 integrin	
stimulation,	 the	 FERM-Kinase	 autoinhibitory	 binding	 is	 disrupted	 (1)	 allowing	 FAK-Y397	
autophosphorylation	(2).	This	 leads	to	the	formation	of	an	HS2	binding	site	recognized	by	Src	
(3).	The	dual	FAK-Src	enzyme	can	further	phosphorylate	FAK	on	Y861	and	Y925	(4).	FAK	also	
contain	 a	 SH3	 binding	 domains	 that	 is	 recognized	 by	 p130Cas	 (5).	 downstream	 signalling	 of	







and	 Schaller,	 2002;	 Cooper,	 2003).	 In	 this	 conformation,	 FAK	 cannot	 be	
autophosphorylated	on	Y397,	preventing	Src	binding	and	downstream	signaling	
(Lietha,	2007).	 FAK	FERM	domain	 contains	p53	binding	domains	 and	nuclear	
localization	 signals	 (Lim,	 2008).	 Nuclear	 exporting	 sequences	 have	 been	
identified	 in	 the	 FERM	 and	 catalytic	 domains,	 suggesting	 that	 FAK	 could	 be	
involved	 in	 signal	 trafficking	 from	 the	 nucleus	 to	 the	 rest	 of	 the	 cell	
(Ossovskaya,	2008).	FAK	FERM	domain	is	able	to	integrate	signals	from	growth	
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1994;	 Xing,	 1994)	 and	 the	 FAK-Src	 dual	 enzymatic	 complex	 is	 involved	 in	
further	 FAK	 phosphorylation	 (for	 example	 on	 Y576/577,	 Y861	 and	 Y925	
residues)	and	in	phosphorylation	of	substrates	clustered	at	focal	contacts,	such	
as	paxillin.	FAK-Y576/Y577	phosphorylation	leads	to	maximal	catalytic	activity,	
but	 the	 exact	 FAK	 or	 Src	 contribution	 to	 substrate	 phosphorylation	 remains	
unclear.	When	autophosphorylated	on	Y397,	FAK	can	also	bind	to	PI3K,	growth-
factor-receptor-bound	 protein-7	 (Grb-7)	 and	 p120RasGAP	 (Mitra,	 2005),	 but	
the	sequential	or	preferential	binding	of	various	proteins	to	FAK	is	unknown.	
It	 has	 been	 recently	 shown	 that	 in	 cancer	 cells	 FAK	 can	 be	
phosphorylated	 on	 the	 Y397	 residue	 by	 oncogenic	 receptor	 tyrosine	 kinases	
even	 in	 the	presence	of	FAK	kinase	 inhibitors	 (Marlowe,	2016).	This	 suggests	
that	 FAK	 kinase	 activity	 and	 FAK-Y397	 phsophorylation	 are	 not	 necessarily	
always	 associated	 and	 that	 FAK-KD	 and	 FAK-Y397F	 mutations	 could	 impair	
different	signaling	pathways.		
Inhibitors	 for	 FAK	 kinase	 domain	 and	 FAK-Y397	 phosphorylation	 are	







FAK	contains	 three	proline-rich	motifs,	one	between	 the	FERM	and	 the	
kinase	 domains	 and	 two	 between	 the	 kinase	 and	 the	 FAT	 domains,	 in	 the	 C-
terminal	 region.	 The	 proline-rich	 motifs	 are	 recognized	 by	 SH3-domain	
containing	 proteins,	 such	 as	 p130Cas,	 that	 is	 important	 for	 promoting	 cell	
migration	through	Rac	activation	(Hanks,	2003;	Chodniewicz,	2004).	FAK-Y861	
phosphorylation	is	crucial	for	Ras	transformation	in	fibroblasts	(Lim,	2004)	and	
was	also	 shown	 to	 increase	 the	binding	of	p130Cas	 (Mitra,	2005).	ASAP1	and	
GRAF	 can	 also	 bind	 the	 FAK-SH3	 domains	 and	 are	 involved	 in	 cytoskeletal	
dynamics	(Parsons,	2003).	Protection	 from	cell	detachment	 induced	apoptosis	
(or	 anoikis)	 has	 also	 been	 linked	with	 FAK-Y861	 phosphorylation,	 suggesting	
that	this	tyrosine	might	play	a	role	in	survival	during	migration	–	an	important	






focal	 contacts	 (Hildebrans,	 1993).	 There	 are	 two	 paxillin	 binding	 sites	 in	 the	
FAT	 domain	 and	 point	 mutations	 specifically	 disrupting	 paxillin	 binding	
highlighted	 the	 importance	 of	 FAK/paxillin	 interaction	 in	 FAK	 subcellular	
localization	 (Scheswohl,	 2008).	 The	 first	 observations	 indicated	 that	 FAK	
deleted	fibroblasts	present	with	impaired	migration,	but	have	more	numerous	
and	 larger	 focal	 contacts,	 suggesting	a	 role	of	FAK	 in	 focal	adhesion	 turnover,	
rather	 than	 formation	 (Ilic,	 1995).	 Since	 then	 extensive	 studies	 have	 proven	
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that	 FAK-Y925	 phosphorylation	 promotes	 FAK	 dissociation	 from	 the	 focal	









FAK/Src	 dual	 enzymatic	 complex	 can	 further	 phosphorylate	 FAK-
Y576/Y577,	 FAK-Y861	 and	 FAK-Y925	 (Calalb,	 1996;	 Schlaepfer,	 2004).	 The	
FAK-Y861	 phosphorylation	 has	 also	 been	 shown	 to	 be	 independent	 of	 FAK-
Y397	phosphorylation	in	specific	cellular	settings	(Abu-Ghazaleh,	2001).	On	the	
other	 hand,	 FAK-Y861	 phosphorylation	 was	 observed	when	 FAK/Src	 binding	
was	 impaired,	 suggesting	 that	 this	 phosphorylation	 is	 not	 exclusively	




FAK	 (Abedi,	 1997;	 Gerber,	 1998,	 Qi,	 2001).	 Activated	 PI3K	 generates	 PIP3	
leading	to	the	recruitment	of	AKT	to	the	cell	membrane	through	its	PH	domain,	
where	 it	 can	 be	 phosphorylated	 in	 its	 kinase	 domain	 on	 T-308	 and	 in	 its	 C-
terminal	 domain	 on	 S-473.	 The	 activated	 AKT	 is	 able	 to	 phosphorylate	 and	
therefore	 inhibit	 pro-apoptotic	 proteins,	 such	 as	 BAD	 and	 pro-caspase-9.	
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Generally,	 FAK	 is	 overexpressed	 in	 highly	 malignant	 tumour	 cells	 and	
has	been	associated,	 in	most	 epithelial	 cancer	 types,	with	 invasive	 cancer	 cell	
phenotype	 (Mitra,	 2005;	 Zhao,	 2009;	 Golubovskaya,	 2009).	 However	 these	
observations	 do	 not	 always	 correlate	 with	 metastasis	 and	 show	 variable	
prognostic	value	(Madan,	2006).	
The	increased	expression	of	FAK	in	a	number	of	cancer	types	has	led	to	
the	 development	 of	 FAK	 inhibitors	 as	 an	 anti-cancer	 therapy.	 Pfizer	 has	
developed	 two	 ATP-binding	 inhibitors	 that	 inhibit	 tumour	 growth	 in	 the	
majority	of	tested	mouse	models	and	in	vitro	impair	cell	migration,	but	have	no	
effect	 on	 cell	 survival,	 growth	or	 apoptosis.	Deletion	of	 FAK	 from	mouse	 skin	
blocked	 chemically-induced	 papilloma	 formation	 and	 malignant	 progression	
(McLean,	2004).	In	another	study,	FAK	knock-out	in	cancer	cells	did	not	affect	
tumour	growth,	suggesting	that	the	efficiency	of	FAK	inhibitors	is	dependent	on	






Genetic	ablation	of	FAK	results	 in	embryonic	 lethality	at	 (E)	8.5	due	 to	
gastrulation	 and	 vascular	 defects	 (Ilic,	 1995)	 a	 phenotype	 that	 resembles	 to	
fibronectin-deficient	 mice.	 Global	 FAK	 Kinase	 dead	 mice	 are	 embryonically	
lethal	 at	 (E)	 9.5,	 presenting	 similar	 vascular	 defects	 and	 haemorrhage	 (Lim,	
2009).	 Global	 deletion	 of	 FAK	 exon	 15	 containing	 the	 Y397	 resulted	 in	 mid-
gestation	 mortality	 between	 (E)	 14.5	 and	 (E)	 16.5,	 with	 developmental	




The	 role	 of	 FAK	 in	 vascular	 development	 has	 been	 confirmed	 using	 a	
mouse	 model	 with	 endothelial-specific	 FAK	 deletion	 (Shen,	 2005;	 Braren,	
2006).	Shen	et	al	showed	that	endothelial	specific	FAK	deletion	caused	lethality	
at	 (E)	11.5,	 two	days	 later	when	 compared	 to	 the	 total	 FAK	KO.	The	 vascular	
defects	 seen	 are	 linked	with	 endothelial	 cell	 migration,	 proliferation	 and	 cell	
survival	 defects.	 Braren	 at	 al	 addressed	 the	 role	 of	 endothelial	 FAK	 in	
development	 using	 a	 Tie2Cre	model	 and	 observed	 dilated	 capillaries	 starting	
from	 (E)	 9.5	 and	 lethality	 between	 (E)	 10.5	 and	 (E)	 11.5.	 In	 this	 model	
endothelial	 cell	 migration	 and	 proliferation	 was	 not	 decreased	 and	 the	
phenotype	 was	 explained	 by	 aberrant	 lamellipodia,	 enhanced	 cell	 death	 and	
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vascular	 pruning.	 Together	 these	 data	 implicate	 FAK	 as	 essential	 to	
developmental	angiogenesis.	
Endothelial	 specific	 FAK	 Kinase	 Dead	 (KD)	 mutation	 in	 embryos	
revealed	 FAK	 Kinase	 dependent	 vascular	 barrier	 function	 (Zhao,	 2010).	 The	
FAK-KD	mutation	was	achieved	by	replacing	the	lysine	at	the	454	position	with	
an	 arginine	 (FAK-K454R).	 The	 endothelial	 specific	 FAK-KD	 mice	 exhibited	
reduced	blood	vessel	density	 in	 the	embryo	brain,	 increased	vessel	diameters	
and	 lethality	 at	 embryonic	 day	 (E)	 13.5.	 In	 this	 study,	 the	 FAK-KD	mutation	
seems	 to	 rescue	 the	 defective	 survival	 observed	 in	 FAK	 deleted	 endothelial	
cells,	 suggesting	 that	other	FAK	elements	are	 involved	 in	endothelial	 cell	pro-
survival	 signaling.	 Endothelial	 specific	 FAK-KD	 knock-in	mice	 also	 revealed	 a	
role	for	FAK	in	control	of	VEGF-stimulated	vascular	permeability	(Chen,	2012)	
and	further	studies	indicate	that	upon	VEGF	stimulation,	FAK	is	able	to	directly	





response	 were	 observed	 in	 FAK	 floxed	 mice	 crossed	 with	 mice	 carrying	 a	
tamoxifen	 induced	Cre	under	 the	control	of	 the	5’	endothelial	enhancer	of	 the	
stem	cell	leukaemia	locus	(End-SCL-Cre-ERT)	and	this	is	thought	to	be	due	to	a	
compensatory	 effect	 of	 Pyk2	 for	 the	 FAK	 loss	 (Weis,	 2008).	
Immunocompromised	mice	were	used	in	a	tamoxifen-inducible	Tie2-CreERT	FAK	
Knock-out	model	and	highlighted	FAK	requirement	 in	 the	Blood-Brain	Barrier	
(BBB)	 integrity	 and	 tumoral	 angiogenesis	 in	 gliomas	 (Lee,	 2010).	 Inducible	
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endothelial	 specific	 FAK	deletion	 in	 the	 absence	 of	 Pyk2	 compensation	 led	 to	
decreased	 tumour	growth	and	angiogenesis	 (Tavora,	2010).	 In	 this	study	FAK	
floxed	mice	were	crossed	with	mice	carrying	a	tamoxifen	inducible	Cre,	driven	
by	 the	 endothelial	 specific	 PDGFb	 promoter	 (Claxton,	 2008).	 Together	 these	











of	 the	 respective	 tyrosine	 by	 a	 phenylalanine	 (Tavora,	 2014a).	 Figure	 1.5	
shows	the	genetic	alterations	present	in	PDGFb-iCreERT2;FAKfl/fl;R26FAKKI	mice	
before	 (A),	 during	 (B)	 and	 after	 (C)	 tamoxifen	 administration,	 as	 well	 as	 the	
impact	of	these	genetic	modifications	on	protein	knockout	and	expression.	This	
mouse	 model	 allows	 addressing	 the	 role	 of	 FAK-Y397	 and	 FAK-Y861	






The	 Cre-positive	 inducible	 mouse	 contains	 the	 same	 genetic	 alterations	 as	 the	 Cre-negative	
mice,	 with	 the	 addition	 of	 a	 Cre	 transgene:	 (A)	 The	 Cre	 recombinase	 transgene	 is	 under	 the	
endothelial-specific	 Pdgfb	 promoter,	 allowing	 the	 expression	 of	 Cre	 only	 in	 endothelial	 cells,	
while	 the	 endogenous	 FAK	 gene	 and	 the	 STOP	 cassette	 are	 flanked	 by	 loxP	 sites.	 (B)	 Upon	
tamoxifen	administration,	Cre	 translocates	 to	 the	nucleus,	 recognises	 the	 loxP	sequences,	 and	














the	 inactivation	 of	 these	 FAK	 phosphorylations	 on	 the	 tumour	 endothelial	
compartment	 as	 well	 as	 on	 the	 tumour	 mass	 itself	 will	 be	 analysed.	 The	
endothelial	 specific	 FAK-KO	 mouse	 model	 has	 shown	 a	 decrease	 in	 tumour	




and	 pericyte	 coverage	 will	 be	 investigated.	 The	 endothelial	 specific	 FAK-KO	






affected	 by	 FAK-Y397F	 or	 FAK-Y861F	mutation,	mouse	 lung	 endothelial	 cells	








8.5	 (Sigma,	Dorset,	UK),	 10mM	EDTA	at	 pH	8,	 100mM	NaCl	 (BDH	Laboratory	
Supplies,	Poole,	UK)	and	0.2%	SDS.	Proteinase	K	(Roche,	Welwyn	Garden	City,	
UK)	was	diluted	to	0.1mg/mL	in	Tail	lysis	buffer.	




Ear	 or	 tail	 snips	 were	 digested	 overnight	 at	 56°C	 in	 100μL	 Tail	 lysis	
buffer,	 supplemented	 with	 0.1mg/mL	 Proteinase	 K.	 To	 precipitate	 the	 DNA,	






buffer	 and	 stored	 at	 -20C.	 Prior	 to	 PCR,	 the	 primers	 were	 diluted	 to	
10μmworking	 solution	 and	 1μL	 of	 each	 primer	 was	 added	 to	 the	 PCR	 mix,	
except	 for	 the	betaglobulin	primers,	 in	which	case	0.75μL	of	each	primer	was	
used.	 For	 each	 PCR	 reaction	 1μL	 DNA	 was	 used	 in	 a	 total	 volume	 of	 25μL	
Megamix	(Cambio,	Cambridge,	UK).		
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in	 50mL	 PBS,	 passed	 through	 a	 70μm	 cell	 strainer	 (BD	 Falcon,	 Bedford,	 MA,	
USA)	 and	 counted	 using	 the	 Automated	 Cell	 Counter	 (Scepter	 2.0,	 Millipore).	
The	cell	suspension	concentration	was	adjusted	to	107	cells/mL	(for	B16F0	and	




The	 GgP+E	 packing	 cell	 line	 was	 grown	 Dulbecco’s	 Modified	 Medium	




rpm	 for	 15	minutes	 and	 passed	 through	 a	 0.45μm	 filter.	 Polybrene	 (8μg/mL	
final	concentration)	was	added	after	the	filtration	step.	
Freshly	prepared	retrovirus	was	used	to	infect	endothelial	cells.	In	some	








The	 solution	was	 autoclaved	 30min	 at	 65°C	 and	 stored	 at	 4°C.	 Tissue	 culture	
flasks	were	coated	with	0.1%	Gelatine,	1%	Collagen	(PureCol	5005-B,	lot	6200,	
1mg/mL,	 Advanced	 BioMatrix),	 1%	 Fibronectin	 (Hu	 Plasma	 Fibronectin,	
1mg/mL,	 lot	2272678,	Millipore)	mix	and	 incubated	at	37°C	 for	2	hours	or	at	





40%	 HAM-F12	 (Sigma	 N6658),	 20%	 Hyclone	 serum	 (Thermo	 Scientific	 SH	
30071.03;	 lot	 SLBC9940V)	 and	 was	 supplemented	 with	 10mg/mL	 Heparin	
(Sigma-Aldrich;	 H3149-1MU),	 Glutamine	 (Glutamax	 35050,	 Invitrogen),	
Penicillin/Streptavidin	 (Sigma	 P4333)	 and	 Endothelial	 Cell	 Growth	
Supplements	(Harbor	Bio-Products;	1003).	
MLEC	 Medium	 was	 supplemented	 with	 500nM	 4-hydroxytamoxifen	





lungs	 removed,	 stored	 in	 Optimem	 Medium	 on	 ice,	 any	 fat	 and	 blood	 clots	
removed,	briefly	 rinced	 in	70%	Ethanol	and	stored	 in	 ice-cold	MLEC	Medium.	
Lungs	from	each	mouse	were	separately	minced	and	incubated	in	3	mL	of	100	
	 40	
E.U.	 Type	 I	 Collagenase	 (Gibco	 Invitrogen,	 Paisley,	 UK)	 for	 75	 minutes.	 The	
digested	tissue	was	then	syringed	up	and	down	3	times	with	the	a	21G	syringe	
(BD	 Microlance;	 304432),	 then	 2	 times	 with	 19G	 syringe	 (BD	 Microlance;	
301500),	 followed	 by	 a	 passage	 through	 a	 70μm	 cell	 strainer	 (BD	 Falcon;	
352350).	The	single-cell	suspension	was	spun	down	at	1200	rpm	for	5	minutes;	





Within	 48h	 of	 the	 cell	 isolation,	 cells	 were	 incubated	 at	 4°C	 for	 20	
minutes	 in	 ice-cold	 MLEC	 medium	 to	 prevent	 internalization	 of	 surface	
receptors,	 followed	by	30	minutes	 incubation	at	4°C	with	a	rat	anti-FCγRII/III	
antibody	 solution	 (BD	 Biosciences;	 553142;	 1/100	 in	 PBS).	 Cells	 were	 then	
washed	 once	 with	 ice-cold	 PBS	 and	 incubated	 at	 4°C	 for	 30	 minutes	 with	 a	
magnetic	 bead	 conjugated	 sheep	 anti-rat	 antibody	 (Invitrogen	 Dynabeads;	
110.35).	After	3	washes	with	ice-cold	PBS	cells	were	trypsinised,	supplemented	
with	medium	 and	 transferred	 in	 a	 tube	 placed	 in	 a	 magnetic	 holder.	 After	 5	
minutes	the	bead-attached	macrophages	were	held	in	the	wall	of	the	tube.	The	




The	 procedure	 described	 in	 section	 4.4	was	 repeated	 using	 a	 rat	 anti-
ICAM2	antibody	solution	(BD	Parmingen;	553326;	1/100	in	PBS)	and	the	bead	
attached	 endothelial	 cells	 were	 held	 in	 the	 wall	 of	 tube.	 The	 medium	 was	
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aspirated	 and	 discarded	 and	 the	 bead	 attached	 endothelial	 cells	 were	
resuspended	in	MLEC	and	plated	in	a	pre-coated	flask.	
The	positive	sorting	step	was	performed	twice	to	ensure	endothelial	cell	




MLEC	 were	 immortalised	 24	 hours	 after	 the	 first	 positive	 sort	 using	
polyoma-middle-T-antigen	retroviral	transfection.	The	retrovirus	was	prepared	
as	described	 in	 section	3.	Endothelial	 cells	were	 infected	 for	4	hours	and	 this	





Endothelial	 cells	 were	 trypsined	 and	 counted;	 106	 endothelial	 cells	 were	
spanned	 for	 10	minutes	 at	 1200	 rpm	 and	 resuspended	 in	 100μL	 transfection	
solution	 (Nucleofactor	 Kit,	 VPB-1002,	 AmaxaTH	 HUVEC).	 The	 appropriate	
plasmid	was	added	to	the	cell	suspension	and	the	transfection	was	performed	










the	mRNA	 level	 using	 the	RT-QPCR	 technique.	 For	 this	 endothelial	 cells	were	
lysed	 using	 RNA	 lysis	 buffer	 (RPE	 +	 beta	 mercaptoethanol)	 and	 RNA	 was	
extracted	 with	 RNA	 Extraction	 Kit	 (Qiagen;	 74104)	 and	 reverse	 transcribed	
with	 high-capacity	 cDNA	 Reverse	 Transcription	 kit	 (Applied	 Biosystems;	
79254).	Real	 time	PCR	was	performed	with	custom	made	primers	and	probes	


























buffer.	 The	 Bio-Rad	 DC	 protein	 assay	 kit	 (Bio-Rad	 laboratories,	 Hercules,	 CA,	
USA)	 was	 used	 according	 to	 the	 manufacturer’s	 guidelines	 to	 determine	 the	
protein	concentration	for	each	sample.	
The	 protein	 concentration	was	 adjusted	 between	 lysates	 using	 Sample	





	 Resolving	gels	 for	8%	polyacrylamide	gel	was	prepared	according	 to	 the	
following	 recipe:	 2.7ml	 30%	Acrylamide	 (National	 Diagnostics,	 UK),	 2.5ml	 4X	
Resolving	 Buffer	 (National	 Diagnostics,	 UK),	 4.8ml	 Distilled	 Water,	 100μL	
Ammonium	 persulphate	 (APS)	 10%	 (w/v)	 (National	 Diagnostics,	 UK),	 6μL	
TEMED	 (National	 Diagnostics,	 UK).	 This	 resolving	 gel	 was	 poured	 into	 pre-





330μL	 30%	 Acrylamide	 (National	 Diagnostics,	 UK),	 0.5mL	 Stacking	 Buffer	
(National	 Diagnostics,	 UK),	 1.15mL	 Distilled	 Water,	 20μL	 Ammonium	
persulphate	(APS)	10%	(w/v)	(National	Diagnostics,	UK),	2μL	TEMED	(National	
Diagnostics,	UK).	The	stacking	gel	was	left	to	polymerise	and	the	comb	was	then	




loaded	 into	 the	 wells	 and	 the	 gel	 was	 run	 at	 125	 volts	 until	 the	 desired	
separation	was	achieved.	
	 Resolved	 proteins	 were	 then	 transferred	 from	 the	 gel	 into	 a	 Hybond	
nitrocellulose	 transfer	membranes	 (GE,	Paisley,	UK),	 by	 assembling	a	 transfer	
‘sandwich’	composed	of,	from	bottom	to	top:	two	sponges,	two	Whatman	paper	
sheets,	 the	 gel,	 the	membrane,	 two	Whatman	paper	 sheets,	 two	 sponges.	 The	
transfer	 “sandwich”	was	placed	 in	 the	 transfer	 apparatus	 (Invitrogen,	Paisley,	
UK),	 put	 in	 a	 transfer	 tank	 and	 immersed	 in	 1X	 transfer	 buffer.	 The	 transfer	
buffer	was	composed	of	0.025M	Tris,	0.192M	glycine	(National	Diagnostics,	UK),	
20%	 methanol	 (Fisher	 Scientific,	 Leicestershire,	 UK)	 and	 the	 transfer	 was	
performed	at	35	volts	for	1	hour	and	30	minutes.	
	 At	the	end	of	the	transfer	step,	the	membranes	were	immersed	in	Ponceau	






Membranes	 were	 blocked	 in	 5%	 BSA/TBS-0.1%Tween-20	 (Sigma,	
Dorset,	 UK)	 for	 1	 hour,	 then	 incubated	 with	 the	 primary	 antibody	 diluted	
1/1000	 in	 blocking	 solution	 overnight	 at	 4C.	 After	 three	 5-minute	washes	 in	
TBS-0.1%Tween-20,	 the	 membrane	 was	 incubated	 with	 the	 appropriate	





The	 films	 were	 developed	 with	 a	 Kodak	 X-OMAT	 100A	 film	 processor	 (East	
Kodak	Company,	New	York,	USA).	The	 following	antibodies	were	used:	Mouse	
anti-FAK	(clone	77/FAK,	BD	Biosciences,	Oxford,	UK),	Mouse	anti-myc	(Abcam,	





Endothelial	 cells	were	plated	 in	6cm	dishes,	 left	 to	grow	overnight	and	
lysed	using	sample	buffer.	Protein	concentration	was	determined	as	previously	
described	 and	matched	 amongst	 lysates	 using	 sample	 buffer.	 The	 lysate	 was	
incubated	with	membranes	containing	antibodies	against	a	panel	of	 cytokines	
(Mouse	 Cytokine	 Array	 panel	 A,	 R&D	 Systems,	 Proteome	 Profiler	 Array,	
ARY006).	All	the	steps	and	the	quantifications	were	performed	according	to	the	
manufacturer’s	 protocol.	 Briefly,	 the	 array	 membranes	 were	 incubated	 for	 1	
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hour	 in	 2mL	 of	 Array	 Buffer	 6	 on	 a	 rocking	 platform	 shaker.	 Meanwhile	 the	






and	 incubated	 for	 30	minutes.	 After	 three	washes	 in	 1X	Wash	Buffer,	 1mL	of	
Chemi	Reagent	Mix	was	evenly	pipetted	into	each	membrane	and	incubated	for	
1	minute.	The	membrane	was	subsequently	placed	into	a	autoradiography	film	









To	prepare	Tamoxifen	 for	 intra-peritoneal	 injection	500	mg	Tamoxifen	
(T5648-5G	Sigma	lot:	SLBB0439V)	was	dissolved	in	5mL	100%	ethanol,	for	30	
minutes	 at	 42°C	 with	 occasional	 vortexing,	 prior	 to	 the	 addition	 of	 45mL	
autoclaved	Corn	Oil	 (Sigma	C8267).	The	 solution	was	vortexed	 for	2	minutes,	
aliquoted	and	stored	at	-20°C	for	up	to	6	months.	Each	experimental	mouse	was	
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Five	 to	 seven	 days	 after	 tamoxifen	 treatment,	 mice	 were	 anesthetised	
with	Isofluorane	(Abbot)	and	subcutaneously	injected	into	the	flank	with	100μL	
of	 1x107	 B16F0	mouse	melanoma	 cells	 or	 1x107	 CMT19T	 carcinoma	 cells	 or	












injected	 with	 100μL	 of	 anti-PE-PECAM	 antibody	 (BioLegends,	 clone	 390,	
102498)	10	minutes	prior	to	tumour	dissection.	The	tumours	were	snap-frozen,	
kept	 at	 -80°C	 and	 stained	 for	 endomucin	 as	 described	 in	 section	 8.3;	 this	







injected	with	 100μL	 of	 anti-PE-PECAM	 antibody	 as	 described	 in	 the	 previous	
section.	Hoechst	33342	was	 injected	 intra-venously	1	minute	prior	 to	 tumour	
dissection.	The	tumours	were	snap-frozen	and	kept	at	-80C.	This	methodology	




Mice	 carrying	 subcutaneous	 size-matched	 tumours	 were	 intra-




















A	 week	 prior	 to	 dissection,	 mice	 was	 injected	 with	 tamoxifen	 as	
described	 in	 Section	8.1.	The	mice	were	killed	by	 cervical	 dislocation	 and	 the	
heart	and	lungs	removed	and	the	aortic	ring	assay	was	performed	as	described	
previously	 (Masson	et	al,	2002;	Reynolds	et	al,	2004).	The	aortas	were	gently	
separated	 from	 the	 spine	 and	 placed	 in	 OptiMEM	 (Life	 Technologies,	 51985-
026)	 supplemented	 with	 100U/mL	 of	 penicllin/streptomycin	 (Invitrogen,	
Paisley,	 UK).	 The	 aortas	 were	 cleaned	 of	 fat,	 blood/blood	 cloths,	 and	
conjunctive	 tissue	 under	 sterile	 conditions	 using	 a	 dissecting	microscope	 and	
were	 subsequently	 cut	 into	 20-25	 rings	 per	 aorta.	 The	 rings	 were	 starved	
overnight	in	OptiMEM	at	37°C	/	10%	CO2	and	at	the	end	of	the	starvation	time	
were	embedded	in	50μL	of	Collagen	matrix.	The	collagen	matrix	was	prepared	
by	mixing	 1.2	 mg/mL	 Collagen	 Type	 I	 (Millipore,	 08-115)	 and	 1.1mL	 of	 10X	
DMEM	 (Gibco,	 12800-017)	 supplemented	 with	 distilled	 water	 to	 10mL.	 The	
aortic	ring	containing	collagen	matrix	was	left	to	polymerize	for	30	minutes	at	
37°C	/	10%	CO2	and	150μL	of	OptiMEM	containing	2.5%	FCS	and	either	VEGF	
(30ng/mL)	 or	 Ang2	 (10ng/mL)	 or	 VEGF+Ang2	 (30ng/mL	 +	 10ng/mL,	
respectively)	or	PBS	(as	a	control)	were	added	per	well.	Media	was	changed	on	
Monday/Wednesday/Friday	by	 removing	75μL	of	 the	media	and	adding	75μL	







in	 70%	 ethanol	 for	 up	 to	 one	 week.	 The	 Barts	 Cancer	 Institute	 Pathology	
Department	performed	sample	paraffin-embedding	procedures	and	5μm	thick	
sections	were	mounted	onto	glass	slides	and	kept	at	room	temperature.	Prior	to	
staining,	 paraffin	 sections	were	 de-waxed	 in	 two	 separate	 xylene	 baths	 (BDH	
Laboratory	 Supplies,	 Poole,	 UK)	 for	 5	 minutes	 each	 and	 re-hydrated	 in	 five	
separate	 baths	 of	 graded	 ethanol	 (100%,	 100%,	 80%,	 70%	 and	 50%)	 for	 2	
minutes	 each.	 The	 slides	 were	 immediately	 used	 for	 immunofluorescence	
staining.	
If	 immunohistochemistry	 had	 to	 be	 performed	 on	 paraffin	 embedded	
tissue,	 endogenous	 peroxidase	 was	 inactivated	 using	 Methanol	 (Fisher	


















antibody	 (clone	 V7C7,	 Santa	 Cruz	 Biotechnology,	 CA,	 USA)	 diluted	 1/200	 in	
5%BSA/PBS	 overnight	 at	 4C.	 After	 three	 10-minute	 washes	 with	 PBS	 0.02%	
Triton	 X-100,	 the	 slides	 were	 incubated	 with	 Alexa	 fluoro	 488	 goat	 anti-rat	
antibody	(Invitrogen,	Paisley,	UK)	diluted	1/100	in	5%BSA/PBS	for	45	minutes	
at	room	temperature.	Sections	were	washed	three	times	with	PBS	0.02%	Triton	
X-100,	 one	 time	 with	 distilled	 water	 and	 mounted	 in	 Prolong	 Gold	 anti-fade	
reagent	with	DAPI	 (Invitrogen,	Paisley,	UK).	Alternatively,	 after	 the	 last	wash,	
sections	 were	 incubated	 for	 5	 minutes	 with	 DAPI	 (Invitrogen,	 Paisley,	 UK)	
diluted	1/10	000	in	water,	followed	by	a	10	minute	was	in	water	and	mounted	
in	Prolong	Gold	anti-fade	reagent	(without	DAPI)	(Invitrogen,	Paisley,	UK).	
The	 endomucin-positive	 blood	 vessels	 were	 visualised	 and	 counted	 at	
the	Zeis	Axioplan	microscope	and	tumour	blood	vessel	density	was	calculated	
by	dividing	the	number	of	endomucin-positive	blood	vessels	counted	across	the	
entire	 midline	 tumour	 sections	 by	 the	 section	 area.	 Representative	 pictures	
were	taken	at	the	confocal	microscope	at	40X	magnification.	









rehydrated	 and	 fixed	 with	 Methanol+H2O2,	 as	 previously	 described.	 Antigen	


















	 DPX-mounted	 slides	were	 left	 to	dry	overnight	 and	 the	next	day	 slides	












stained	 for	 endomucin	 following	 the	 immunofluorescence	protocol	 previously	
described.	
PE-PECAM-positive	 blood	 vessels	 (perfused	 blood	 vessels)	 and	
endomucin-positive	 blood	 vessels	 (all	 blood	 vessels)	 were	 counted	 at	 40X	
magnification	at	 the	Axioplan	microscope	and	at	 least	100	PE-PECAM-positive	
blood	 vessels	 were	 counted	 per	 tumour.	 The	 percentage	 of	 functional	 blood	






At	 the	 experimental	 endpoint	 tumour-bearing	mice	were	 injected	with	





The	 frozen	 tumours	were	processed	 in	 the	dark	and	sections	were	cut,	
mounted	using	anti	fade	reagent	(without	DAPI)	and	5	fields	per	tumour	were	
photographed	 at	 40X	magnification	 using	 the	Axioplan	microscope.	 The	 same	
threshold	 was	 used	 across	 all	 the	 fields	 and	 tumours	 for	 the	 blue	 channel	
(DAPI)	and	also	for	the	red	channel	(PE-PECAM).	
Image	 J	 software	was	used	 to	determine	 the	Hoechst-positive	area	and	
the	PE-PECAM	positive	area	for	each	field	and	the	Hoechst/PE-PECAM	ratio	was	
calculated	 for	 each	 field.	 Hoechst/PE-PECAM	 ratios	 from	 each	 of	 the	 5	
photographed	fields	were	averaged	to	obtain	Hoechst/PE-PECAM	ratio	for	each	
tumour.	
To	 determine	 if	 the	 studied	 endothelial	 mutations	 have	 an	 effect	 on	
Hoechst	 leakage,	 Hoechst/PE-PECAM	 ratios	 were	 compared	 between	 Cre	
negative	and	Cre	positive	groups.	
	
8.7. Blood	 vessel	 and	 pericyte	 double	 immunostaining	
and	Pericyte	coverage	quantitation	
Tumour	 sections	 were	 fixed	 with	 Acetone	 as	 previously	 described,	
blocked	 with	 5%BSA/PBS	 and	 incubated	 with	 a	 solution	 containing	 anti-
Endomucin	 antibody	 (Endomucin	 clone	 C7	 Santa	 Cruz;	 1/200	 in	 in	
5%BSA/PBS)	and	anti-NG2	antibody	(Millipore	AB5320;	1/200	in	5%BSA/PBS)	
at	4°C	overnight.	The	next	day,	 slides	were	washed	 three	 times	 in	PBS	1X	 for	
5min	 and	 incubated	 with	 a	 secondary	 antibody	 mixture	 containing	 anti-rat	
Alexa	 546	 antibody	 (Invitrogen,	 Paisley,	 UK;	 1/100	 in	 5%BSA/PBS)	 and	 anti-
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were	 used	 to	 acquire	 fluorescence	 images	 at	 40X	 magnification	 of	
approximately	 10	 fields	 per	 tumour.	 For	 each	 tumour,	 blood	 vessels	 were	








in	 PBS	 for	 1	 hour	 at	 room	 temperature.	 The	 sections	 were	 next	 incubated	
overnight	 at	 4°C	 with	 FITC-conjugated	 antibody	 (HPI	 Burlington;	 MA01803)	
diluted	 1/10	 in	 PBS.	 After	 three	 PBS	 washes,	 the	 sections	 were	 mounted	 in	
Prolong	Gold	anti-fade	reagent	with	DAPI	(Invitrogen,	Paisley,	UK).	
Fluorescence	 images	 were	 captured	 using	 a	 CDD	 camera	 Hamamatsu	
C4742-95	and	a	Zeiss	Axioplan	microscope.	The	area	positive	for	staining	was	
determined	using	the	ImageJ	software	and	the	hypoxic	index	was	calculated	as	












FAK-Y861F	mutations	 on	 tumour	 growth	 and	 in	vivo	 tumour	 angiogenesis,	 as	
well	as	on	growth	 factor	 induced	angiogenesis	 in	vivo	and	ex	vivo.	Mouse	 lung	
endothelial	 cells	 isolated	 from	 the	 mutated	 mice	 were	 used	 for	 preliminary	
mechanistic	studies	in	vitro	and	the	effects	of	endothelial	FAK-Y397F	and	FAK-
Y861F	mutations	 on	 cytokine	 production	will	 be	 presented	 at	 the	 end	 of	 this	
chapter.	
	
1. Elucidating	 the	 effects	 of	 endothelial	 FAK-Y397F	 and	
FAK-Y861F	 mutations	 on	 tumour	 growth	 and	
angiogenesis	
This	 section	will	 present	 the	 in	 vivo	 effect	 of	 endothelial	 specific	 FAK-
Y397F	 and	 EC-FAK-Y861F	 mutations	 on	 tumour	 growth	 and	 angiogenesis.	








(which	 are	 derived	 from	 B16F0	 melanoma	 cells)	 secrete	 high	 levels	 of	 PlGF	
(Zhang,	 2008).	 	 The	 aim	 of	 this	 section	 is	 to	 investigate	 if	 and	 how	 the	
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endothelial	 specific	 FAK-Y397F	 and	 FAK-Y861F	 mutations	 impact	 tumour	
growth,	 in	three	distinct	tumour	models	that	differ	 in	terms	of	tissue	of	origin	
and	growth	factor	secretion	profile.	
The	 generation	 and	 characterisation	of	 the	 transgenic	mice	will	 briefly	
be	 presented	 in	 the	 next	 part,	 before	 presenting	 the	 tumour	 growth	 and	
angiogenesis	data.	
	
1.1. Generation	 and	 characterisation	 of	 mutant	
endothelial-specific	FAK-Y397F	and	FAK-Y861F	mice	
PDGFb-iCreERT2;	 FAK	 fl/fl;	 R26FAK-KI	 mice	 that	 display	 inducible	




crossing	 PDGFb-iCreERT2;	 FAK	 fl/fl	 mice	 (aslo	 referred	 to	 as	 EC-FAKKO	 mice)	
with	mice	bearing	one	of	 the	 following	constructs	(WT	or	FAK-Y397F	or	FAK-
Y861F)	 in	 the	 Rosa26	 locus.	 After	 a	 series	 of	 crossings,	 PDGFb-iCreERT2;	 FAK	
fl/fl;	 R26FAK-KI/KI	 mice	 were	 obtained	 and	 experiments	 addressing	 the	
involvement	in	tumour	angiogenesis	and	tumour	growth	of	two	residues	FAK-
Y397	 and	 FAK-Y861	 when	 mutated	 specifically	 in	 endothelial	 cells	 were	
performed.	 Similar	 experiments	 (B16F0	 and	 CMT19T	 tumour	 growth,	 sponge	
assay	and	aortic	assay)	have	been	conducted	with	the	endothelial	specific	FAK-
KO	 mice,	 have	 been	 published	 (Tavora,	 2010)	 and	 are	 regularly	 referred	 to	
throughout	this	thesis	as	the	EC-FAKKO	phenotype.	
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Since	 the	 endothelial	 specific	 knock	 out	 and	 knock	 in	 mutation	 is	
tamoxifen-inducible,	 the	 mice	 did	 not	 present	 with	 antenatal	 or	 post-natal	
mortality.	 Tamoxifen	 administration	 lead	 to	 the	 knock	 out	 of	 the	 endogenous	
mouse	FAK	and	the	knock	in	of	the	mutated	version	of	FAK	in	the	Rosa26	locus.	
Mice	 were	 given	 a	 diet	 containing	 tamoxifen	 throughout	 the	 experimental	
procedure,	 as	 well	 as	 two	 consecutive	 tamoxifen	 injections	 intra-peritoneally	
five	to	seven	days	before	the	injection	of	tumour	cells,	to	avoid	major	variations	
in	 tamoxifen	 administration	 due	 to	 variation	 in	 diet	 up-take.	 In	 the	 case	 of	
tumour	 studies	 the	 characterisation	 of	 the	 tumour	 tissues	 was	 performed	 at	
least	24	days	after	the	first	tamoxifen	injection.1	
I	was	additionally	responsible	 for	managing	the	backcross	of	 these	and	











Table	 3.1	 shows	 the	detailed	nomenclature	 for	 various	 genotypes	 and	
the	abbreviations	that	will	be	used	throughout	the	thesis.		
																																																								
1	For	 the	 sponge	 assay,	microvessel	 infiltration	was	determined	21	days	 after	
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Genotype Abbreviation used Proteins expressed 
FAKfl/fl Cre-neg; FAKcontrol mFAK expressed 
Pdgfb-iCreERT2;FAKfl/fl; Cre-pos; FAKKO mFAK not expressed 
FAKfl/fl;R26FAKWT/WT Cre-neg; FAK-WTKI mFAK expressed 
chFAK-WT not expressed 
Pdgfb-iCreERT2;FAKfl/fl; 
R26FAKWT/WT 
Cre-pos; FAK-WTKI mFAK not expressed 
chFAK-WT expressed 
FAKfl/fl;R26FAKY397F/Y397F Cre-neg; FAK-Y397FKI mFAK expressed 
chFAK-Y397F not expressed 
Pdgfb-iCreERT2;FAKfl/fl; 
R26FAKY397F/Y397F 
Cre-pos; FAK-Y397FKI mFAK not expressed 
chFAK-Y397F expressed 
FAKfl/fl;R26FAKY861F/Y861F Cre-neg; FAK-Y861FKI mFAK expressed 
chFAK-Y861F not expressed 
Pdgfb-iCreERT2;FAKfl/fl; 
R26FAKY861F/Y861F 






During	my	 PhD	 I	was	 responsible	 for	maintaining	 the	 FAK-WTKI,	 FAK-
Y397FKI	 and	 FAK-Y861FKI	 colonies	 (approximately	 200	 cages)	 and	 was	
responsible	 for	 all	 the	 breeding,	 weaning,	 genotyping,	 experimental	 mouse	
allocation	and	protocols.	DNA	sequencing	identified	the	mutations	in	each	of	the	
mutant	 lines	 (Figure	 3.1	 A).	PCR	genotyping	was	 carried	out	on	all	mice	and	
identified	the	presence	of	the	floxed	sequences	in	the	endogenous	FAK	gene	(on	





FAK	 knockin	 and	 mouse	 FAK	 deletion	 was	 confirmed	 for	 each	 Cre	 positive	
endothelial	 cell	 line	 isolated	 from	 these	 mice	 (Figure	 3.1D).	 Additionally,	
Western	 blot	 analysis	 confirmed	 FAK	 expression	 in	 Cre-neg	 and	 Cre-pos	
endothelial	 cell	 lines,	 with	 myc-tagged	 FAK	 expression	 only	 in	 Cre-pos	
endothelial	cells	line	as	expected.	The	biochemical	outcome	of	the	mutants	was	




is	 mutated,	 subsequent	 phosphorylation	 at	 FAK-Y861	 residue	 is	 impaired,	 at	
least	 in	basal	 conditions	 (i.e.	non-stimulated	with	exogenous	Growth	Factors).	
The	total	amount	of	FAK	protein,	as	visualized	after	probing	for	total	FAK	and	
for	myc	indicates	that	FAK-Y397F	protein	is	expressed	in	slightly	higher	mounts	
when	 compared	 to	 FAK-WT,	 whereas	 FAK-Y861F	 protein	 is	 less	 expressed	
when	compared	to	FAK-WT.	Cre	pos;	FAK-Y861FKI	cell	line	presents	with	some	
residual	signal	as	detected	by	the	anti-FAK-Y861	phospho	antibody.	This	might	
be	 due	 to	 the	 quality	 of	 the	 antibody	 and	 its	 ability	 to	 detect	 exclusively	







equivalent	 to	 the	 wild-type	 mouse	 FAK	 protein,	 at	 least	 for	 the	 investigated	
parameters.		
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1.2. Endothelial-specific	 FAK-WTKI	 rescues	 the	 tumour	
growth	and	tumour	angiogenesis	EC-FAKKO	defect	
It	has	been	published	that	FAK-deletion	in	endothelial	cells	delays	B16F0	
tumour	 growth	 (Tavora,	 2010).	 Thus	 to	 test	 if	 the	 KO/KI	 system	 functions	
efficiently,	 a	WT	 version	 of	 FAK	was	 knocked-in	 to	 determine	 if	 this	 leads	 to	
phenotype	rescue	 thus	validating	 the	system.	Cre-neg;	FAK-WTKI	and	Cre-pos;	
FAK-WTKI	 mice	 were	 injected	 subcutaneously	 with	 B16F0	 melanoma	 cells	 a	
week	 after	 tamoxifen	 administration,	 and	 tumour	 growth	 was	 monitored.	
B16F0	tumour	cells	injected	in	Cre-pos;	FAK-WTKI	mice	grow	in	a	similar	way	to	
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FAK-Y861FKI	 mice.	 The	 FAK-WTKI	 mice	 have	 the	 TAT	 DNA	 codon	 encoding	 for	 a	 tyrosine	 at	
position	 397	 and	 861.	 The	 FAK-Y397FKI	 mice	 have	 the	 TTT	 DNA	 codon	 encoding	 for	 a	
phenylalanine	 at	 the	 397	 position	 and	 an	 intact	 TAT	 DNA	 codon	 encoding	 for	 a	 tyrosine	 at	
position	 861.	 The	 FAK-Y861FKI	 mice	 have	 the	 TAT	 DNA	 codon	 encoding	 for	 a	 tyrosine	 at	















amount	of	mouseFAK	(msFAK)	mRNA	and	of	chickenFAK	(chFAK)	 in	all	 the	cell	 lines.	Results	
show	 that	msFAK	was	 present	 in	 Cre-negative	 cell	 lines	 and	 absent	 in	 Cre-positive	 cell	 lines,	
whereas	chFAK	was	absent	in	Cre-negative	cell	lines	and	present	in	Cre-positive	cell	lines.	
(E)	Mouse	 lung	 endothelial	 cells	were	 isolated	 from	mice	 from	all	 the	 genotypes	 and	protein	
lysates	were	 used	 to	 determine	 the	 total	 FAK	protein,	 as	well	 as	 pY397-FAK	 and	pY861-FAK	
phosphorylations	and	the	myc-tagged	chFAK	protein.	Results	show	that	FAK	is	phosphorylated	
at	Y397	in	all	lysates	except	for	the	lysate	generated	using	the	Cre-pos;	FAK-Y397FKI	endothelial	
cells,	 indicating	 that	FAK	 is	not	phosphorylated	at	 this	residue	when	this	mutation	 is	present.	
Similarly	FAK	is	phosphorylated	on	Y861	in	all	lysates	except	for	the	lysate	generated	using	the	
Cre-pos;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y861FKI	 endothelial	 cells,	 suggesting	 that	 FAK	 is	 not	
phosphorylated	on	the	mutated	Y861F	residue;	additionally	this	data	indicate	that,	 in	baseline	
conditions,	FAK-Y861	phosphorylation	 is	decreased	 in	Cre-pos;	FAK-Y397FKI	when	comparing	
to	 Cre-negative	 controls.	 In	 all	 cell	 lysates	 similar	 levels	 of	 total	 FAK	 protein	 are	 observed,	







Figure	 3.2:	 Reintroducing	 a	WT	 version	 of	 FAK	 in	 endothelial	 cells	 does	
not	affect	B16F0	tumour	growth	in	vivo	
Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	 mice	 were	 given	 subcutaneous	 injections	 of	
syngeneic	B16F0	melanoma	cells,	5-7	days	after	tamoxifen	injection.	Tumour	dimensions	were	
measured	 from	 day	 9	 to	 day	 21	 and	 tumour	 volumes	 calculated	 (Volume	 =	 0.52	 x	 Length	 x	
Width2).	At	day	21	tumours	were	dissected	and	photographed	(A).	No	significant	difference	in	
tumour	growth	was	determined	between	Cre-neg;	FAK-WTKI	and	Cre-pos;	FAK-WTKI	mice	 (B)	































To	 determine	 tumour	 blood	 vessel	 density,	 endomucin-positive	 blood	
vessels	were	counted	across	the	midline	sections	of	size-matched,	age-matched	
tumours	and	the	number	of	blood	vessels	was	divided	by	the	area	of	the	tumour	
section.	 Results	 indicate	 that	 there	 is	 no	 difference	 in	 blood	 vessel	 density	
between	 the	 tumours	 grown	 in	 Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	





examine	 this	 I	 measured	 changes	 in	 blood	 vessel	 perimeter	 (indicative	 of	
possible	 changes	 in	 blood	 flow	 and	 vessel	 maturation);	 blood	 vessel	 leakage	
(indicative	of	changes	in	vessel	maturation);	perciyte	coverage	(also	indicative	
of	vessel	maturation)	and	tumour	hypoxia	(a	 indicator	of	oxygen	delivery	into	
the	tumour).	 	Studying	these	parameters	 is	 important	as	 it	can	 indicate	which	
features	of	 the	 tumour	vasculature	can	be	affected	by	FAK	mutations	and	can	
also	offer	a	direction	regarding	 the	signalling	pathways	 that	 could	be	affected	
by	these	mutations.	Tumour	blood	vessel	perimeter	was	analysed	using	Image	J	
software.	 The	 perimeter	 of	 at	 least	 fifty	 blood	 vessels	 per	 sample	 was	
determined.	The	percentage	of	vessels	 that	were	 less	 than	50µm;	50-100	µm;	
100-200	µm	or	200	µm	or	more	were	calculated	and	results	show	that	there	is	
no	different	in	tumour	blood	vessel	perimeter	between	Cre-neg;	FAK-WTKI	and	




reagent	 (without	 any	 immunostaining)	 and	 the	 levels	 of	 Hoechst	 leakage	
assessed	by	measuring	the	areas	of	Hoechst-stained	nuclei	around	PE-PECAM-
positive	 vessels	 (as	 detected	 by	 the	 PE-conjugated	 anti-PECAM-antibody	
injected	 in	 the	 tail	 vein	10	minutes	before	 culling	 the	mice	and	dissecting	 the	
tumours).	 Results	 showed	 that	 the	 levels	 of	 Hoechst	 leakage	 were	 similar	 in	
Cre-neg;	 FAK-WTKI	 and	Cre-pos;	 FAK-WTKI	mice	 (Figure	 3.4	 B).	 Blood	 vessel	
maturation	was	measured	by	counting	the	numbers	of	pericyte-positive	blood	
vessels.	Tumour	sections	were	double	stained	for	endomucin	and	NG2	marker	
of	 pericytes	 and	 the	 percentage	 of	 vessels	 with	 associated	 pericytes	 was	
calculated	 after	 histological	 examination.	 Results	 showed	 no	 significant	
difference	 in	 blood	 vessel	 pericyte	 coverage	 between	 the	 Cre-neg;	 FAK-WTKI	
and	Cre-pos;	FAK-WTKI	mice	(Figure	3.4	C).	In	order	to	determine	if	knocking-
in	 a	 WT	 version	 of	 FAK	 in	 endothelial	 cells	 affects	 tumour	 hypoxia,	





Lastly,	 to	 confirm	 the	 tumour	 growth	 results	 in	 a	 second	 tumour	 type,	
Lewis	 Lung	 Carcinoma	 (LLC)	 cells	 were	 injected	 subcutaneously	 in	 Cre-neg;	
FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	 mice,	 one	 week	 after	 tamoxifen	
administration.	As	 for	 the	B16F0	tumour	growth,	LLC	tumour	growth	was	the	








Figure	 3.3:	 Reintroducing	 a	WT	 version	 of	 FAK	 in	 endothelial	 cells	 does	
not	affect	B16F0	tumour	angiogenesis	in	vivo	
Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	 mice	 were	 given	 subcutaneous	 injections	 of	
syngeneic	B16F0	melanoma	cells	after	tamoxifen	treatment.	Tumour	blood	vessel	density	was	
calculated	 by	 counting	 all	 the	 endomucin-positive	 blood	 vessels	 across	 the	 entire	 midline	
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	(A)	 Endomucin-stained	 tumour	 sections	were	 photographed	 at	 the	Axioplan	microscope	 and	
representative	 pictures	 show	 blood	 vessels	 stained	 in	 green.	 The	 perimeter	 of	 at	 least	 fifty	
blood	vessels	per	 sample	was	measured	using	 the	 Image	 J	 software.	The	percentage	of	blood	
vessels	 that	 were	 less	 than	 50mm;	 50-100	 mm;	 100-200	 mm	 or	 200	 mm	 or	 more	 was	
determined	for	Cre-neg;	FAK-WTKI	and	Cre-pos;	FAK-WTKI	samples	and	no	significant	difference	
was	observed	between	the	two	genotypes.	Scale	bar	=	300	μm.	
(B)	 Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	mice	 bearing	 21-day-old	B16F0	 subcutaneous	





(C)	Endomucin-	and	NG2-double	 stained	 tumour	sections	were	photographed	at	 the	Axioplan	




(D)	B16F0	 tumour-burdened	Cre-neg;	 FAK-WTKI	 and	Cre-pos;	 FAK-WTKI	mice	were	 given	 tail	
vein	 injections	 of	 Pimonidazole	 probe.	 FITC-anti-Pimonidazole	 antibody	 was	 used	 to	 detect	
hypoxic	 regions	 (in	 green)	 and	 blood	 vessels	 are	 detected	 by	 endomucin	 staining	 (in	 red).	
Pictures	 taken	 at	 the	 Axioplan	 were	 quantified	 and	 the	 percentage	 of	 hypoxic	 area	 was	
















Figure	 3.5:	 Reintroducing	 a	WT	 version	 of	 FAK	 in	 endothelial	 cells	 does	
not	affect	LLC	tumour	growth	in	vivo	
Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	 mice	 were	 given	 subcutaneous	 injections	 of	
syngeneic	 LLC	 carcinoma	 cells,	 5-7	 days	 after	 tamoxifen	 injection.	 Tumour	 dimensions	 were	
measured	 from	 day	 6	 to	 day	 24	 and	 tumour	 volumes	 calculated	 (Volume	 =	 0.52	 x	 Length	 x	
Width2).	 No	 significant	 difference	 in	 LLC	 tumour	 growth	 was	 determined	 between	 Cre-neg;	
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A	week	 after	 tamoxifen	 administration,	 Cre-neg;	 FAK-Y397FKI	 and	Cre-
pos;	 FAK-Y397FKI	 mice	 were	 injected	 subcutaneously	 with	 B16F0	 melanoma	
cells	 and	 tumour	 volumes	 were	 determined	 over	 time.	 Results	 showed	 that	
B16F0	tumour	growth	was	significantly	inhibited	in	Cre-pos;	FAK-Y397FKI	mice	
when	compared	with	Cre-neg;	FAK-Y397FKI	mice	 (Figure	 3.6).	Results	shown	




of	 the	 experimental	 repeats.	 Figure	 3.7	 A	 shows	 representative	 pictures	 of	
endomucin	stained	blood	vessels	from	size-matched	tumours	grown	in	Cre-neg;	





1	It	 can	 be	 challenging	 to	 perform	 three	 different	 ante-mortem	 procedures	 at	
the	 end	 of	 a	 tumour	 growth	 experiment	 containing	 up	 to	 15	mice	 per	 group,	
therefore	at	least	two	experimental	repeats	were	necessary.	Later	on,	concerns	
were	raised	about	the	length	of	the	tumour	growth	experiment	and	the	impact	
that	 this	 could	 have	 on	 the	 statistical	 outcome,	 therefore	 the	 tumour	 growth	
experiment	 was	 stopped	 at	 Day	 15,	 Day	 17	 and	 Day	 21.	 Noteworthy	 is	 that	
tumour	growth	is	impaired	in	Cre-pos;	FAK-Y397FKI	mice	when	compared	with	
Cre-neg;	 FAK-Y397FKI	 mice	 independently	 of	 the	 length	 of	 the	 experiment.	
Further	 concerns	 were	 raised	 regarding	 performing	 the	 tumour	 growth	
experiments	 independently	 for	 each	 KI	 colony,	 therefore	 a	 tumour	 growth	
experiment	with	mice	 from	 the	 three	 KI	 colonies	 (WT-KI,	 FAK-Y397F	 KI	 and	




specific	 inactivation	 of	 FAK-Y397F	 phosphorylation	 is	 sufficient	 to	 decrease	
tumour	 angiogenesis.	 Appendix	 I	 Figure	 S3.3	 shows	 data	 from	 the	 second	
experimental	repeat	and	confirms	the	delayed	tumour	angiogenesis.	
In	 order	 to	 determine	 if	 delayed	 tumour	 growth	 is	 a	 consequence	 of	
delayed	 tumour	 angiogenesis,	 B16F0	 tumour	 cells	 were	 injected	
subcutaneously	 in	 Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	 mice,	 a	
week	after	tamoxifen	administration	and	allowed	to	grow	until	Day	8.	Tumours	
were	 dissected	 at	 this	 early	 time	 point	 and	 blood	 vessel	 density	 was	
determined.	 Representative	 pictures	 are	 shown	 in	 Figure	 3.7	 C	 and	 results	
indicate	 that	 tumour	 angiogenesis	 is	 decreased	 in	 tumours	 grown	 in	Cre-pos;	
FAK-Y397FKI	mice	when	compared	 to	Cre-neg;	FAK-Y397FKI	mice	and	suggest	
that	a	defect	in	tumour	angiogenesis	is	present	before	a	delay	in	tumour	growth	
is	 observed	 (Figure	 3.7	 D).	 Overall	 this	 data	 indicates	 that	 impaired	 tumour	
growth	might	be	a	consequence	of	delayed	angiogenesis.	
Although	blood	vessel	density	was	reduced	in	B16F0	tumours	grown	in	
Cre-pos;	 FAK-Y397FKI	mice	when	 compared	with	 Cre-neg;	 FAK-Y397FKI	mice,	
no	differences	in	tumour	blood	vessel	perfusion	in	8-day	old	(Figure	3.8	A)	and	
in	 15-day	 old	 B16F0	 tumours	 (Figure	 3.8	 B)	 was	 observed,	 indicating	 that	
endothelial	FAK-Y397F	mutation	does	not	affect	tumour	blood	vessel	perfusion.	
Tumour	blood	vessel	perimeter	(Figure	3.8	C),	Hoechst	leakage	(Figure	3.8	D)	
or	pericyte	 coverage	 (Figure	 3.8	 E)	was	also	 analysed	and	no	difference	was	
observed	 between	 genotypes.	 Lastly,	 the	 reduced	 number	 of	 blood	 vessels	 in	
Cre-pos;	FAK-Y397FKI	mice	was	associated	with	a	significant	increase	in	tumour	




In	 short,	 the	 results	 indicate	 that	 the	 mutation	 in	 EC-FAK-Y397F	 is	
sufficient	 to	 delay	 B16F0	 subcutaneous	 tumour	 growth	 and	 tumour	
angiogenesis	 but	 does	 not	 affect	 other	 parameters	 of	 blood	 vessels.	
Nevertheless,	 FAK-Y397F	 mutation	 in	 endothelial	 cells	 specifically	 increases	











Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	B16F0	melanoma	cells,	5-7	days	after	tamoxifen	injection.	Tumour	dimensions	were	
measured	 from	day	 11	 to	 day	 17	 and	 tumour	 volumes	 calculated	 (Volume	=	 0.52	 x	 Length	 x	
Width2).	 At	 day	 17	 tumours	 were	 dissected	 and	 photographed	 (A).	 Tumour	 growth	 was	
significantly	 retarded	 in	Cre-pos;	FAK-Y397FKI	mice	when	 compared	 to	Cre-neg;	FAK-Y397FKI	




































B16F0	 tumour	 blood	 vessel	 density	 was	 calculated	 by	 counting	 all	 the	 endomucin-positive	
blood	vessels	across	the	entire	midline	tumour	section	from	size-matched	17-day-old	or	8-day-
old	 tumours.	 Representative	 images	 of	 endomucin-stained	 blood	 vessels	 from	 17-day-old	
tumours	from	both	genotypes	are	shown	(A)	and	the	quantified	data	indicated	that	FAK-Y397F	
mutation	in	endothelial	cells	delays	B16F0	tumour	angiogenesis	(B).	To	determine	if	the	delay	
in	 angiogenesis	 occurs	 before	 the	 difference	 in	 tumour	 volumes	 is	 observed,	 blood	 vessel	
density	was	quantified	in	8-day-old	B16F0	tumours.	Representative	images	and	quantification	
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neous	 tumours,	 were	 given	 tail	 vein	 injections	 of	 anti-PE-PECAM	 antibody	 (red	 signal)	 and	
Hoechst	 (blue	 signal).	 Midline	 tumour	 sections	 were	 mounted	 from	 size-matched	 tumours	
(without	any	immunofluorescence	staining).	Representative	pictures	and	area	of	Hoechst/area	
of	 PE-PECAM	 ratio	 is	 shown	 and	 statistical	 analysis	 indicates	 that	 introducing	 FAK-Y397F	
mutation	in	the	endothelium	does	not	affect	Hoechst	Leakage.	Scale	bar	=	100μm.	
(E)	Endomucin-	and	NG2-double	 stained	 tumour	sections	were	photographed	at	 the	Axioplan	
microscope	 and	 the	 percentage	 of	 naked	 blood	 vessels	 (no	 pericyte	 coverage)	 and	 the	
percentage	 of	 blood	 vessels	 partially	 or	 completely	 covered	 by	 pericytes	 was	 calculated	 and	
results	 show	 that	 there	 is	 no	 difference	 in	 pericyte	 coverage	 between	 the	 two	 genotypes.	
Endomucin-stained	 endothelial	 cells	 are	 shown	 in	 red,	 whereas	 NG2-stained	 perycites	 are	
shown	in	green.	Scale	bar	=	100μm.	
(F)	 B16F0	 tumour-burdened	 Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	 were	 given	
intraperitoneal	injections	of	Pimonidazole	probe.	FITC-anti-Pimonidazole	antibody	was	used	to	
detect	 hypoxic	 regions	 (shown	 in	 green).	 Endomucin-positive	 endothelial	 cells	 are	 shown	 in	
red.	 Pictures	 taken	 at	 the	 Axioplan	 were	 quantified	 and	 the	 percentage	 of	 hypoxic	 area	 was	
determined	by	dividing	the	Pimonidazole	stained	area	by	the	total	field	area.	This	data	indicate	





CMT19T	 carcinoma	 cells	were	 used	 as	 a	 second	 subcutaneous	 tumour	
model	 and	 were	 injected	 in	 Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	
mice	a	week	after	tamoxifen	administration.	The	results	were	similar	to	those	of	
the	B16F0	tumours	grown	in	Cre-neg;	FAK-Y397FKI	and	Cre-pos;	FAK-Y397FKI	
mice.	 CMT19T	 tumour	 volumes	 were	 measured	 over	 time	 and	 a	 significant	
difference	was	seen	starting	from	Day	15	(Figure	3.9).	At	Day	24	the	tumours	
grown	 in	 Cre-pos;	 FAK-Y397FKI	 mice	 were	 significantly	 smaller	 than	 the	
tumours	 grown	 in	 the	 Cre-neg;	 FAK-Y397FKI	mice,	 indicating	 that	 endothelial	
specific	 inactivation	 of	 FAK-Y397	 phosphorylation	 is	 sufficient	 to	 reduce	
CMT19T	 tumour	 growth.	 At	 Day	 24	 a	 large	 proportion	 of	 Cre	 negative	 mice	
developed	 tumours	 at	 the	 legal	 limit	 and	 had	 to	 be	 culled.	 The	 remaining	
tumours	were	dissected	at	 the	experimental	endpoint	 (Day	28)	and	statistical	
analysis	returned	a	p	value	of	p=0.050	for	the	remaining	set	of	data.	
Size-matched	 tumours	 from	 Day	 28	 were	 used	 to	 quantify	 tumour	




Overall	 the	 CMT19T	 carcinoma	 model	 recapitulates	 the	 B16F0	















Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	 CMT19T	 carcinoma	 cells,	 5-7	 days	 after	 tamoxifen	 injection.	 Tumour	 dimensions	
were	measured	from	day	7	to	day	28	and	tumour	volumes	calculated	(Volume	=	0.52	x	Length	x	
Width2).	 Tumour	 growth	 was	 significantly	 retarded	 in	 Cre-pos;	 FAK-Y397FKI	 mice	 when	
compared	 to	 Cre-neg;	 FAK-Y397FKI	 indicating	 that	 the	 endothelial-specific	 FAK-Y397	































Figure	 3.10:	 Endothelial-specific	 inactivation	 of	 FAK-Y397	 phosphory-
lation	 is	 sufficient	 to	 reduce	CMT19T	carcinoma	 tumour	angiogenesis	 in	
vivo	
Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	CMT19T	carcinoma	cells	after	tamoxifen	treatment.	Tumour	blood	vessel	density	was	
calculated	 by	 counting	 all	 the	 endomucin-positive	 blood	 vessels	 across	 the	 entire	 midline	
tumour	 section	 from	 size-matched	 tumours.	 Representative	 pictures	 of	 endomucin	 stained	
blood	vessels	and	blood	vessel	density	quantification	are	shown	in	(A)	and	(B)	respectively.	The	







































Cre-pos;	 FAK-Y397FKI,	 suggesting	 that	 the	 endothelial	 specific	 FAK-Y397F	
mutation	does	not	affect	LLC	tumour	growth.	However,	in	line	with	my	previous	
results	 with	 B16F0	 and	 CMT19T,	 blood	 vessel	 density	 in	 LLC	 tumours	 was	
decreased	 significantly	 in	 Cre-pos;	 FAK-Y397FKI	 mice	 (Figure	 3.12).1	Thus,	
these	 results	 indicate	 that	 endothelial	 specific	 inactivation	 of	 FAK-Y397	
phosphorylation	 is	 sufficient	 to	 decrease	 LLC	 tumour	 angiogenesis,	 without	
affecting	 LLC	 tumour	 growth.	 Noteworthy,	 blood	 vessel	 perfusion	 was	 not	
















Figure	 3.11:	 Endothelial-specific	 inactivation	 of	 FAK-Y397	 phosphory-
lation	 does	 not	 affect	 LLC	 tumour	 growth	 in	 spite	 of	 impairing	 tumour	
angiogenesis	in	vivo	
Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	 LLC	 carcinoma	 cells,	 5-7	 days	 after	 tamoxifen	 injection.	 Tumour	 dimensions	 were	
measured	 from	 day	 6	 to	 day	 24	 and	 tumour	 volumes	 calculated	 (Volume	 =	 0.52	 x	 Length	 x	

























Figure	 3.12:	 Endothelial-specific	 inactivation	 of	 FAK-Y397	 phosphory-
lation	leads	to	a	decrease	LLC	tumour	angiogenesis	in	vivo	











































Figure	 3.13:	 Endothelial-specific	 inactivation	 of	 FAK-Y397	 phosphory-
lation	does	not	affect	blood	vessel	perfusion	in	LLC	tumours	in	vivo	
LLC	tumour	bearing	Cre-neg;	FAK-Y397FKI	and	Cre-pos;	FAK-Y397FKI	mice,	were	injected	with	
anti-PE-PECAM	antibody	 into	 the	 tail	 vein	 ten	minutes	prior	 to	 sacrifice.	Midline	LLC	 tumour	
sections	 from	size-matched	 tumours	were	 stained	 for	 endomucin	and	 representative	pictures	
were	taken	at	the	Confocal	microscope.	Blood	vessels	(in	green),	PE-PECAM-antibody	perfused	
blood	 vessels	 (in	 red)	 and	 their	merge	 from	Cre-neg;	 FAK-Y397FKI	 and	Cre-pos;	 FAK-Y397FKI	
























































Y861FKI	 until	Day	17	 and	 results	 are	 presented	 in	Figure	 3.14	A.	These	data	
indicate	 that	 endothelial-specific	 FAK-Y861F	 mutation	 does	 not	 affect	 B16F0	
tumour	 growth.	 These	 results	 are	 representative	 of	 two	 independent	
experimental	repeats	and	the	second	repeat	is	shown	in	Appendix	 I	Figure	A	









subcutaneous	 growth	 (Figure	 3.15	 A).	 Tumour	 sections	 were	 stained	 for	







3.15	 C).	 This	 result	 indicates	 that	 tumour	 angiogenesis	 is	 affected	 by	 the	
endothelial	specific	FAK-Y861F	mutation	as	early	as	Day	7	post	B16F0	tumour	
cell	 inoculation.	Surprisingly	when	this	parameter	was	analysed	 in	21-day	old	
B16F0	 tumours,	 no	 delay	 in	 tumour	 angiogenesis	was	 observed	 between	 the	
two	genotypes	 (Figure	 3.15	 D).	This	data	highlights	 the	possibility	 that	FAK-
Y861F	 mutated	 endothelium	 is	 able	 to	 compensate	 the	 initially	 observed	
angiogenesis	impairment.	
	Overall	these	results	suggest	that	the	endothelial	specific	inactivation	of	
FAK-Y861	phosphorylation	 reduces	 tumour	angiogenesis	at	 least	until	Day	17	
post	tumour	cell	inoculation,	but	does	not	affect	tumour	growth.	
Tumour	 blood	 vessel	 perfusion	 was	 determined	 in	 7-day	 old	 (Figure	
3.16	 A)	 and	 in	17-day	old	B16F0	 tumours	 (Figure	 3.16	 B)	 and	 results	 show	
that	 endothelial	 FAK-Y861F	 mutation	 does	 not	 affect	 tumour	 blood	 vessel	
perfusion.	 Blood	 vessels	 in	 B16F0	 tumours	 were	 assessed	 for	 blood	 vessel	
perimeter	measurements	(Figure	3.16	C),	Hoechst	leakage	(Figure	3.16	D)	and	
pericyte	 coverage	 (Figure	 3.16	 E).	 No	 significant	 differences	 between	
genotypes	were	 observed.	 Lastly,	 analysis	 of	 tumour	 hypoxia	 also	 showed	 no	
significant	differences	 in	B16F0	tumours	grown	 in	Cre-pos;	FAK-Y861FKI	mice	














Figure	 3.14:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
lation	does	not	affect	B16F0	tumour	growth	in	vivo	
Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice	 were	 subcutaneously	 injected	 with	
syngeneic	 B16F0	melanoma	 cells,	 5-7	 days	 after	 tamoxifen	 administration.	 Tumour	 size	 was	
measured	 from	 day	 8	 to	 day	 17	 and	 tumour	 volumes	 calculated	 (Volume	 =	 0.52	 x	 Length	 x	
Width2).	 At	 day	 17,	 tumours	 were	 dissected	 and	 photographed	 (A).	 The	 endothelial-specific	
FAK-Y861F	mutation	does	not	impair	tumour	growth,	as	no	significant	difference	was	observed	




















































Figure	 3.15:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
lation	decreases	B16F0	tumour	angiogenesis	in	the	early	stages	of	tumour	
formation	
Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice	 were	 subcutaneously	 injected	 with	
syngeneic	B16F0	melanoma	cells,	5-7	days	after	 tamoxifen	administration.	Tumour	cells	were	
allowed	 to	 grow	 until	 Day	 17	 and	 blood	 vessel	 density	 was	 quantified	 in	 age-matched,	 size-
matched	 tumours	 (A).	 A	 decrease	 in	 tumour	 angiogenesis	 was	 observed	 and	 representative	
pictures	are	shown	(B).	Blood	vessel	density	was	quantified	in	7-day	old	(C)	and	21-day	old	(D)	



















































































Figure	 3.16:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
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Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice	 bearing	 8-day	 old	 B16F0	 tumours	 (A)	
and	17-day	old	B16F0	tumours	(B)	were	given	anti-PE-PECAM	antibody	 injection	 into	the	tail	
vein	ten	minutes	prior	to	sacrifice.	Midline	B16F0	tumour	sections	from	size-matched	tumours	
were	 stained	 for	 endomucin.	 The	 number	 of	 PE-PECAM-antibody	 perfused	 tumour	 blood	





perimeter	of	at	 least	 fifty	blood	vessels	per	sample	was	measured	using	the	 Image	 J	software.	








(E)	Endomucin-	and	NG2-double	 stained	 tumour	sections	were	photographed	at	 the	Axioplan	
microscope	 and	 the	 percentage	 of	 naked	 blood	 vessels	 (no	 pericyte	 coverage)	 and	 the	













As	 a	 second	 subcutaneous	 tumour	 model,	 the	 CMT19T	 carcinoma	 cell	
line	 was	 used	 to	 investigate	 the	 effect	 of	 endothelial-specific	 FAK-Y861F	
mutation	on	 tumour	growth	and	angiogenesis.	Cre-neg;	FAK-Y861FKI	and	Cre-
pos;	FAK-Y861FKI	mice	were	injected	with	CMT19T	cells	a	week	after	tamoxifen	




results	 indicate	 there	 is	 no	 significant	 difference	 in	 CMT19T	 tumour	 blood	
vessel	 densities	 (Figure	 3.18).1	This	 result	 indicates	 that	 endothelial	 FAK-
Y861F	 mutation	 does	 not	 affect	 tumour	 angiogenesis	 as	 analysed	 at	 Day	 28.	
Whether	this	mutation	impairs	tumour	angiogenesis	 in	early	stages	of	tumour	











Figure	 3.17:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
lation	does	not	affect	CMT19T	carcinoma	tumour	growth.	
Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	 CMT19T	 carcinoma	 cells,	 5-7	 days	 after	 tamoxifen	 injection.	 Tumour	 dimensions	
were	measured	from	day	6	to	day	28	and	tumour	volumes	calculated	(Volume	=	0.52	x	Length	x	

























Figure	 3.18:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
lation	does	not	affect	CMT19T	carcinoma	tumour	angiogenesis.	
Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	CMT19T	carcinoma	cells,	5-7	days	after	 tamoxifen	 injection.	CMT19T	tumour	blood	
vessel	density	was	calculated	by	counting	all	 the	endomucin-positive	blood	vessels	across	 the	
entire	 midline	 tumour	 section	 from	 size-matched	 tumours.	 Representative	 pictures	 of	
endomucin	stained	blood	vessels	and	blood	vessel	density	quantification	are	shown	in	(A)	and	



































subcutaneously	 into	 Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice	
previously	 administered	 with	 tamoxifen.	 Results	 indicate	 that	 there	 is	 no	
difference	 in	LLC	 tumour	growth	between	Cre-neg;	FAK-Y861FKI	 and	Cre-pos;	
FAK-Y861FKI	 (Figure	 3.19).	 In	 addition,	 no	 difference	 in	 LLC	 tumour	
angiogenesis	 was	 observed	 between	 the	 two	 genotypes	 (Figure	 3.20).	 The	
analysis	 was	 performed	 in	 24-day	 old	 LLC	 tumours	 and	 whether	 a	 delay	 in	
tumour	angiogenesis	is	present	at	earlier	staged	in	tumour	formation	still	needs	
to	be	investigated.	
As	 previously	 observed	 in	 the	 B16F0	 tumour	 model,	 blood	 vessel	




The	 findings	 presented	 in	 this	 section	 show	 that	 inactivating	 the	
endothelial	 specific	 FAK-Y397	 phosphorylation	 leads	 to	 a	 delay	 in	 tumour	
angiogenesis,	 for	 the	 three	 studied	 subcutaneous	 tumour	 models	 and	 is	
accompanied	 by	 an	 increase	 in	 tumour	 hypoxia.	 None	 of	 the	 studied	 blood	
vessel	 parameters	 (such	 as	 blood	 vessel	 perimeter,	 perfusion,	 leakage	 or	
pericyte	coverage)	were	affected	by	the	FAK-Y397F	mutation.	








Inactivation	 of	 endothelial	 specific	 FAK-Y861	 phosphorylation	 leads	 to	
delayed	 tumour	 angiogenesis	 in	 the	 early	 stages	 of	 B16F0	 tumour	 formation	
and	at	least	until	Day	17	post	tumour	cell	 inoculation.	This	defect	is	overcome	
by	Day	21	suggesting	that	alternative	mechanisms	that	are	independent	of	FAK-
Y861	 phosphorylation	 become	 activated.	 Noteworthy	 is	 that	 the	 observed	
delayed	angiogenesis	did	not	impair	B16F0	tumour	growth.	
Tumour	 angiogenesis	was	 analysed	 in	 28-day	 old	 CMT19T	 and	 24-day	
old	LLC	tumour	models	and	the	endothelial	FAK-Y861F	mutation	did	not	affect	
tumour	 angiogenesis	 in	 neither	 of	 these	 models.	 Investigating	 tumour	
angiogenesis	at	an	earlier	stage	of	tumour	formation	would	indicate	if	the	data	
obtained	 for	 7-	 and	 17-day	 old	 B16F0	 tumours	 can	 be	 generalized	 to	 all	 the	
studied	models	or	if	it	is	specific	to	B16F0	melanoma	tumours.	








Figure	 3.19:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
lation	does	not	affect	LLC	tumour	growth	or	tumour	angiogenesis	in	vivo	
Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	 LLC	 carcinoma	 cells,	 5-7	 days	 after	 tamoxifen	 injection.	 Tumour	 dimensions	 were	
measured	 from	 day	 6	 to	 day	 24	 and	 tumour	 volumes	 calculated	 (Volume	 =	 0.52	 x	 Length	 x	





























Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	mice	were	 given	 subcutaneous	 injections	 of	
syngeneic	 LLC	 carcinoma	 cells,	 5-7	 days	 after	 tamoxifen	 injection.	 Endomucin-positive	 blood	
vessels	were	 counted	 across	 the	midline	 section	 of	 LLC	 size	matched	 tumours	 and	 the	 blood	
vessel	density	was	determined.	Statistical	 analysis	 shows	 that	endothelial-specific	FAK-Y861F	






































Figure	 3.21:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
lation	does	not	affect	blood	vessel	perfusion	in	LLC	tumours	in	vivo	
LLC	tumour	bearing	Cre-neg;	FAK-Y861FKI	and	Cre-pos;	FAK-Y861FKI	mice,	were	injected	with	
anti-PE-PECAM	antibody	 into	 the	 tail	 vein	 ten	minutes	prior	 to	 sacrifice.	Midline	LLC	 tumour	
sections	 from	size-matched	 tumours	were	 stained	 for	 endomucin	and	 representative	pictures	
were	taken	at	the	Confocal	microscope.	Blood	vessels	(in	green),	PE-PECAM-antibody	perfused	
blood	 vessels	 (in	 red)	 and	 their	merge	 from	Cre-neg;	 FAK-Y397FKI	 and	Cre-pos;	 FAK-Y397FKI	
















































2. Elucidating	 the	 effect	 of	 endothelial	 FAK-Y397F	 and	
FAK-Y861F	 mutations	 on	 growth	 factor	 driven	
angiogenesis	in	vivo	
	
Several	 hypotheses	 could	 explain	 the	 difference	 between	 B16F0,	
CMT19T	and	LLC	 tumour	 growth	and	 the	 associated	 tumour	 angiogenesis	 for	
the	 two	 studied	FAK	mutants.	 For	 sustained	 tumour	 growth	different	 tumour	
types	seem	to	depend	more	or	 less	on	 tumour	angiogenesis	and	the	way	 they	
trigger	 tumour	 angiogenesis	 might	 be	 different.	 More	 precisely,	 the	 main	
growth	 factor,	 or	 the	 cocktail	 of	 growth	 factors,	 secreted	 by	 these	 tumours	
might	 be	 different	 and,	 the	 effect	 of	 the	 endothelial	 FAK	 mutations	 can	 be	
different,	 depending	 on	 the	 growth	 factor(s)	 that	 drive	 angiogenesis.	 To	
determine	 if	 FAK-Y397F	 and	 FAK-Y861F	 mutated	 endothelial	 cells	 react	




Y861F	 mutations	 affect	 angiogenesis	 differently	 depending	 on	 which	 growth	
factor	 is	 driving	 angiogenesis	 in	vivo.	 Briefly,	 the	 procedure	 involved	 treating	










possible	 the	 conditions	 and	 timings	 of	 the	 subcutaneous	 tumour	 growth	
experiments.	 Firstly	 Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	 mice	 were	
given	tamoxifen	five	days	prior	to	sponge	implantation,	which	is	similar	to	what	
was	done	in	tumour	growth	experiments,	where	tumour	cells	where	injected	5-
7	 days	 after	 the	 first	 tamoxifen	 administration.	 Secondly,	 the	 sponges	 were	
implanted	 under	 the	 skin,	 on	 the	 flank	 of	 the	 mice,	 similarly	 to	 where	 the	
tumour	cells	are	injected.	To	mimic	the	early	time	point	as	previously	described	
in	the	tumour	growth	experiments,	sponges	were	dissected	at	Day	7,	but	very	
few	microvessels	had	 infiltrated	 the	 sponges	and	 it	was	unclear	 if	 the	growth	
factors	 had	 a	 pronounced	 angiogenic	 effect	 at	 this	 early	 time	 point	 (data	 not	
shown).	This	was	in	contrast	to	what	had	been	observed	in	7-day	old	tumours	
that	presented	with	a	substantial	blood	vessel	density;	and	this	 is	presumably	
due	 to	 tumours	 containing	 a	 multitude	 of	 growth	 factors	 acting	 together,	 as	
opposed	to	the	one	growth	factor	regularly	injected	into	the	sponge.	Therefore	
to	 study	 the	 effect	 of	 one	 specific	 growth	 factor	 on	 microvessel	 infiltration,	
sponge	assay	studies	at	a	 later	 time	point,	namely	at	Day	14.	To	 this	purpose,	
growth	factors	or	PBS	were	injected	into	the	sponge	on	Mondays,	Wednesdays,	
Fridays	and	a	total	of	five	injections	per	sponge	were	performed	over	2	weeks.	
At	 the	 end	 of	 the	 experiment	 the	 sponges	were	 dissected	 and	 formalin-fixed;	
thin	 sections	 were	 cut	 and	 stained	 for	 the	 endothelial	 marker	 endomucin.	
Figure	 3.22	 A	 shows	 sponge	 fields	 containing	 blood	 vessels	 (stained	 for	
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(Figure	 3.22	 B).	 VEGF	 injected	 sponges	 showed	 an	 increase	 in	 micovessel	
invasion	when	compared	with	PBS	baseline.	No	difference	 in	VEGF-stimulated	
microvessel	 invasion	was	 observed	 between	 Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	
FAK-WTKI	mice	 (Figure	3.22	B)	 indicating	that	the	two	genotypes	respond	to	








every	 other	 day	 starting	 with	 Day	 2	 postimplantation.	 At	 Day	 14	 postimplantation,	 sponges	
were	 harvested,	 fixed	 in	 formalin	 and	 the	 cut	 sections	 were	 stained	 for	 endomucin	 (A).	
Angiogenesis	 was	 quantified	 by	 counting	 the	 endomucin-positive	 blood	 vessels	 across	 the	
sponge	width	at	30X	magnification	and	normalized	to	the	number	of	counted	fields	(B).	VEGF	
administration	 increases	 angiogenesis	 similarly	 in	 Cre-neg;	 FAK-WTKI	 and	Cre-pos;	 FAK-WTKI	
sponges	when	compared	to	PBS	injected	controls,	indicating	that	reintroducing	a	WT	version	of	
























































2.2. Endothelial	 specific	 inactivation	 of	 FAK-Y397	




pos;	 FAK-Y397FKI	 mice	 and	 sponges	 were	 treated	 with	 one	 of	 the	 following:	
VEGF,	PlGF,	bFGF,	Ang2	or	PBS,	as	a	control.	
A	 statistically	 significant	 increase	 in	 the	 number	 of	 blood	 vessels	 per	
field	was	observed	in	VEGF-	(Figure	3.23	A),	PlGF-	(Figure	3.23	B)	or	bFGF-	
(Figure	 3.23	 C)	 treated	 sponges	 implanted	 in	 the	Cre-neg;	FAK-Y397FKI	mice	
when	 compared	 to	 PBS-treated	 sponges	 implanted	 in	 mice	 with	 the	 same	
genotype,	 indicating	 that	 each	 of	 these	 growth	 factors	 is	 able	 to	 trigger	
angiogenesis	in	our	experiments.	
	 To	determine	the	effect	of	the	endothelial	specific	FAK-Y397F	mutation	
on	 in	VEGF-,	 PlGF-	 or	 bFGF-driven	 angiogenesis,	 the	 number	 of	 blood	 vessels	
per	 field	was	 compared	 between	 growth	 factor-treated	 sponges	 implanted	 in	
Cre	neg;	FAK-Y397FKI	and	Cre	pos;	FAK-Y397FKI	mice.	VEGF-,	PlGF-	and	bFGF-
stimulated	 microvessel	 invasion	 was	 reduced	 in	 Cre-pos;	 FAK-Y397FKI	 mice	
when	compared	with	Cre-neg;	FAK-Y397FKI	controls	(Figure	3.23	A,	B	and	C).	
These	 results	 indicate	 that	 the	 endothelial	 specific	 inactivation	 of	 FAK-Y397	
phosphorylation	 is	 sufficient	 to	 impair	 VEGF-,	 PlGF	 and	 bFGF-driven	
angiogenesis.	
Noteworthy	 is	 the	 statistically	 significant	 decrease	 in	 the	 number	 of	
blood	 vessels	 per	 field	 for	 PBS-treated	 sponges	 implanted	 in	 Cre-pos;	 FAK-
Y397FKI	 mice	 when	 compared	 to	 PBS-treated	 sponges	 implanted	 in	 Cre-neg;	
	 107	
FAK-Y397FKI	 mice	 (Figure	 3.23	 B,	 C	 and	 D)1.	 This	 data	 indicates	 that	 the	
endothelial	 specific	 inactivation	 of	 FAK-Y397	 phosphorylation	 may	 impair	
baseline	angiogenesis	even	in	PBS	controls.	
Statistical	 analysis	 of	 the	 data	 presented	 in	Figure	 3.23	 D	 returns	 a	 p	
value	of	p=0.0566	when	comparing	microvessel	 infiltration	in	sponges	treated	
with	 Ang2	 vs	 PBS	 in	 Cre-neg;	 FAK-Y397FKI	 mice,	 which	 is	 very	 close	 to	
statistical	 significance.	 In	 itself	 this	 data	 suggests	 that	 Ang2	 is	 not	 able	 to	
promote	 angiogenesis	 in	 the	 Cre-neg	 control	 mice	 and	 therefore	 cannot	 be	
considered	 as	 a	 pro-angiogenic	 growth	 factor	 in	 this	 experimental	 setting.	
Nevertheless,	 increasing	n-numbers,	or	fine	tuning	the	experimental	design	by	
administering	 Ang2	 more	 often	 or	 in	 higher	 concentrations	 would	 allow	 to	
obtain	a	more	clear	cut	result	in	terms	of	the	ability	of	Ang2	to	induce	or	sustain	
angiogenesis.	 However	 Ang2	 stimulated	microvessel	 invasion	was	 reduced	 in	





Overall	 this	 data	 indicates	 that	 the	 endothelial	 specific	 FAK-Y397	










Figure	 3.23:	 Endothelial-specific	 inactivation	 of	 FAK-Y397	 phosphory-
lation	impairs	VEGF-,	PlGF	and	bFGF-driven	angiogenesis.	
Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	 mice	 were	 given	 subcutaneous	 sponge	
implants,	two	days	after	tamoxifen	administration.	The	sponges	were	injected	with	PBS,	VEGF,	




VEGF	 (A),	 PlGF	 (B)	 or	 bFGF	 (C)	 administration	 increased	 microvessel	 formation	 in	 Cre-neg;	
FAK-Y397FKI	when	compared	to	PBS	 treated	Cre-neg;	FAK-Y397FKI	sponges.	Conversely	VEGF,	
PlGF	 and	bFGF	were	not	 able	 to	 trigger	 angiogenesis	 in	Cre-pos;	 FAK-Y397FKI	 sponges	 to	 the	
same	extend	as	in	Cre-neg;	FAK-Y397FKI	sponges.	(D)	Ang2	failed	to	trigger	angiogenesis	in	Cre	
neg	control	mice;	nevertheless	FAK-Y397F	mutation	impaired	microvessel	invasion	in	Cre-pos;	
FAK-Y397FKI	 sponges	 when	 compared	 to	 Cre-neg;	 FAK-Y397FKI	 Ang2	 treated	 sponges.	
Noteworthy	 FAK-Y397F	mutation	 leads	 to	 a	 delay	 in	microvessel	 infiltration	 even	 in	 the	 PBS	










































































































































2.3. Endothelial	 specific	 inactivation	 of	 FAK-Y861	
phosphorylation	 does	 not	 affect	 VEGF-,	 PlGF-	 and	 bFGF-
driven	 angiogenesis	 and	 allows	 ANG2	 to	 act	 as	 a	 pro-
angiogenic	growth	factor	
	
To	 study	 the	 effect	 of	 the	 endothelial	 specific	 FAK-Y861F	 mutation,	





and	 bFGF	 administration	 leads	 to	 increased	 microvessel	 invasion	 when	
compared	with	PBS.	This	data	 confirms	 that	VEGF,	PlGF	and	bFGF	act	 as	pro-
angiogenic	growth	factors	in	Cre-neg	control	mice.	
To	 determine	 if	 the	 endothelial	 specific	 FAK-Y861F	 mutation	 impairs	
VEGF-,	PlGF-	or	bFGF-driven	microvessel	invasion	into	the	sponges,	the	number	
of	blood	vessels	per	 field	 in	either	VEGF-,	PlGF-	or	bFGF-treated	 sponges	was	
compared	 between	 Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI.	 The	
outcome	 of	 this	 comparison	 indicates	 that	 there	 is	 no	 significant	 difference	
between	 Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 in	 terms	 of	
microvessel	 infiltration	 in	 either	 VEGF-,	 PlGF-	 or	 bGFG-treated	 sponges,	
suggesting	 that	 the	 endothelial	 specific	 FAK-Y861	 phosphorylation	 is	
dispensable	 for	 VEGF-,	 PlGF-	 or	 bFGF-driven	 angiogenesis	 in	 this	 in	 vivo	
experimental	setting.	 	
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	 Of	 note	 is	 that	 the	 endothelial	 specific	 FAK-Y861F	 mutation	 does	 not	
affect	baseline	microvessel	 infiltration,	as	proven	by	comparing	Cre-neg;	FAK-
Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 blood	 vessel	 counts	 after	 PBS	 treatment	
(Figure	3.24).	
	 In	 this	 in	 vivo	 experimental	 setting,	 ANG2	 does	 not	 act	 as	 a	 pro-
angiogenic	growth	factor.	Indeed	the	number	of	blood	vessels	per	field	in	ANG2-
treated	sponges	implanted	in	Cre-neg;	FAK-Y861FKI	mice	was	unchanged	when	
compared	 to	 PBS-treated	 sponges	 implanted	 in	mice	with	 the	 same	 genotype	
(Figure	3.24	D)1.	Surprisingly	microvessel	 infiltration	was	increased	in	Ang2-
treated	sponges	implanted	in	Cre-pos;	FAK-Y861FKI	mice,	suggesting	that	Ang2	
is	 sensed	 as	 a	 pro-angiogenic	 growth	 factor	 by	 the	 FAK-Y861F	 mutated	
endothelium	(Figure	3.24	D).	
Together	 these	 results	 suggested	 that	 the	 endothelial	 specific	 FAK-
Y861F	mutation	does	not	affect	VEGF-,	PlGF-	or	bFGF-driven	angiogenesis	and	




The	 sponge	 assay	 has	 allowed	 dissection	 of	 the	 effect	 of	 four	 different	
growth	 factors	 –	 VEGF,	 PlGF,	 bFGF	 and	 ANG2	 on	 FAK-Y397F	 or	 FAK-Y861F	
mutated	 endothelium	 in	 a	 tumour-free	 environment	 in	 vivo.	 The	 endothelial	
specific	 inactivation	 of	 FAK-Y397	 phosphorylation	 impairs	 VEGF-,	 PlGF-	 and	





with	 the	 finding	 that	 this	mutation	 delays	 tumour	 angiogenesis	 for	 the	 three	
studied	 subcutaneous	 tumour	models	 (B16F0,	 CMT19T	 and	LLC).	 In	 contrast,	
VEGF-,	PlGF-	and	bFGF-stimulated	angiogenesis	was	not	affected	in	FAK-Y861F	
mutated	 endothelium	 and	 this	 finding	 is	 in	 line	 with	 unaffected	 tumour	
angiogenesis	 in	 late	 time	 point	 B16F0	 CMT19T	 and	 LLC	 tumour	models.	 The	
reason	 for	 delayed	 tumour	 angiogenesis,	 when	 FAK	 is	 mutated	 on	 the	 Y861	
residue,	 in	 the	 early	 time	 point	 of	 B16F0	 tumour	 model	 needs	 further	
investigation.	




these	 in	 vivo	 secreted	 factors,	 the	 ex-vivo	 aortic	 ring	 assay	 was	 used	 to	
investigate	 the	 affect	 of	 the	 endothelial	 specific	 FAK-Y397F	 and	 FAK-Y861F	








Figure	 3.24:	 Endothelial-specific	 inactivation	 of	 FAK-Y861	 phosphory-
lation	does	not	affect	VEGF-,	PlGF-	or	bFGF-driven	angiogenesis	and	allows	
Ang2	to	act	as	a	pro-angiogenic	growth	factor.	






fields.	 VEGF-,	 PlGF-	 or	 bFGF-triggered	 microvessel	 infiltration	 was	 not	 affected	 by	 the	
endothelial	 specific	 FAK-Y861F	mutation.	Ang2	was	 able	 to	 trigger	microvessel	 infiltration	 in	










































































































































3. Elucidating	 the	 effect	 of	 endothelial	 FAK-Y397F	 and	
FAK-Y861F	 mutations	 on	 growth	 factor	 driven	
angiogenesis	ex	vivo	
Aortic	ring	assay	was	performed	in	order	to	further	investigate	the	effect	
of	 FAK-Y397F	 and	 FAK-Y861F	mutations	 in	 endothelial	 cells	 on	 VEGF-driven	
sprouting	angiogenesis,	as	well	as	on	VEGF+Ang2	signalling.	This	assay	allows	
investigating	 the	 effect	 of	 one	 or	 several	 growth	 factors	 on	 sprouting	
angiogenesis.	The	source	of	growth	factors	in	this	assay	is	primarily	exogenous	
(added	 and	 controlled	 during	 the	 experiment)	 and	 the	 only	 other	 source	 of	
growth	factors	might	be	the	aorta	 itself.	This	 is	an	advantage	compared	to	the	
sponge	 assay,	where	 growth	 factors	 can	be	 secreted	by	 a	 large	 variety	 of	 cell	
types	present	in	the	sponge	as	well	as	produced	by	cells	elsewhere	in	the	body	
and	then	delivered	systemically	into	the	sponge.		





3.1. Validation	 of	 the	 KO/KI	 system	 in	 the	 ex	 vivo	 aortic	
ring	assay	




1	Each	 aortic	 ring	 assay	was	 done	with	 3	mice	 per	 genotype	 and	 the	 aortic	 ring	 assays	were	




every	 other	 day	 and	 the	 number	 of	 sprouts	was	 counted	 for	 each	 aortic	 ring	
starting	 from	Day	4.	Results	 presented	 in	Figure	 3.25	 show	 that	 the	 average	
number	 of	 spouts	 per	 aortic	 ring	 from	 Cre-neg;	 FAK-WTKI	 is	 statistically	
increased	 upon	 VEGF	 treatment	 when	 compared	 to	 PBS	 treatment.	 This	
indicates	that	VEGF	is	able	to	trigger	aortic	ring	sprouting	in	control	mice.	The	
same	effect	 is	seen	in	Cre-pos;	FAK-WTKI	mice,	 indicating	that	knocking	in	WT	















collagen	matrix	 and	 treated	with	VEGF	or	 PBS	 as	 a	 control.	 The	number	 of	 sprouts/ring	was	
counted	at	Day	4,	Day	5,	Day	7	and	Day	10	and	averaged	at	each	time	point.	Statistical	analysis	
indicates	that,	when	compared	to	PBS	control	group,	VEGF	treatment	lead	to	an	increase	in	the	



























3.2. Endothelial-specific	 inactivation	 of	 FAK-Y397	
phosphorylation	impairs	VEGF-driven	sprouting	
The	same	experimental	procedure	was	used	for	aortic	rings	from	Cre-neg;	FAK-
Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	 mice.	 As	 previously,	 VEGF	 was	 able	 to	
trigger	 aortic	 ring	 sprouting	 in	 rings	 from	 Cre-neg;	 FAK-Y397FKI	mice	 (when	
compared	 to	PBS	 treatment	of	 rings	 from	Cre-neg;	FAK-Y397FKI	mice)	and,	 at	
day	10,	the	number	of	spouts	for	VEGF	treated	rings	from	Cre-pos;	FAK-Y397FKI	
mice	 was	 statistically	 decreased	 (Figure	 3.26	 A).	 This	 result	 indicates	 that	





pos;	 FAK-Y397FKI	 mice,	 indicating	 that	 ANG2	 alone	 is	 not	 a	 pro-angiogenic	
factor	(Figure	3.26	B)	and	this	finding	is	 in	line	with	the	data	obtained	in	the	
sponge	assay.		The	ANG2+VEGF	combination	showed	an	increase	in	microvessel	





result	 has	 to	 be	 interpreted	 with	 caution	 as	 there	 is	 no	 significant	 increase	
between	 the	 VEGF	 vs	 VEGF+Ang2	 treated	 rings	 from	 Cre-pos;	 FAK-Y397FKI,	








Figure	 3.26:	 Endothelial	 specific	 FAK-Y397F	 mutation	 impairs	 VEGF-
driven	sprouting	angiogenesis,	but	is	partially	rescued	by	Ang2	addition.	
Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	 mice	 were	 given	 tamoxifen	 5	 days	 prior	 to	




indicates	 that	 the	number	 of	 sprouts	 per	 ring	was	decreased	 in	VEGF-treated	 rings	dissected	
from	 Cre-pos;	 FAK-Y397FKI	mice	when	 comparing	 to	 VEGF-treated	 rings	 from	 Cre-neg;	 FAK-
Y397FKI,	 indicating	 that	 FAK-Y397	 phosphorylation	 in	 endothelial	 cells	 is	 essential	 for	 VEGF-
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factor-driven	 aortic	 ring	 sprouting,	 the	 aortic	 ring	 assay	was	 performed	with	
aortas	from	Cre-neg;	FAK-Y861FKI	and	Cre-pos;	FAK-Y861FKI	mice.	Figure	3.27	
A	shows	 the	obtained	 results	 and	 indicates	 that	VEGF	 is	 able	 to	 trigger	aortic	
ring	sprouting	 in	both	Cre-neg;	FAK-Y861FKI	and	Cre-pos;	FAK-Y861FKI	aortas	
(when	 compared	 to	 PBS	 treatment),	 proving	 that	 endothelial	 specific	
inactivation	 of	 FAK-Y861	 phosphorylation	 does	 not	 affect	 VEGF-driven	
angiogenesis	 in	 vivo.	 These	 results	 confirm	 the	 previously	 obtained	 data	 on	
VEGF-driven	angiogenesis	in	sponge	assay.	
In	section	3.2.3	of	this	chapter,	 I	have	shown	that	ANG2	administration	
in	 sponges	 implanted	 in	 Cre-pos;	 FAK-Y861FKI	 mice	 leads	 to	 an	 increase	 in	
microvessel	density	and	indicates	that	ANG2	acts	as	a	pro-angiogenic	factor	in	
FAK-Y861F	 mutated	 endothelial	 cells.	 Aortic	 ring	 assay	 with	 Cre-neg;	 FAK-
Y861FKI	and	Cre-pos;	FAK-Y861FKI	aortas	 in	 the	presence	of	ANG2	alone	or	 in	
combination	with	VEGF	(ANG2+VEGF)	was	performed	to	further	investigate	the	
effect	 of	 the	 endothelial	 specific	 FAK-Y861F	 mutation	 on	 ANG2-driven	
angiogenesis.	Results	presented	in	Figure	3.27	B	show	that	ANG2	alone	is	not	
able	 to	 trigger	 angiogenesis	 neither	 in	 Cre-neg;	 FAK-Y861FKI,	 nor	 in	 Cre-pos;	
FAK-Y861FKI	aortas,	 indicating	 that	ANG2	 is	not	pro-angiogenic	 in	FAK-Y861F	
mutated	aortic	rings.	When	treated	with	ANG2	and	VEGF,	aortic	ring	sprouting	
is	triggered	to	a	similar	level	in	Cre-neg;	FAK-Y861FKI	and	Cre-pos;	FAK-Y861FKI	
rings,	 indicating	 that	 the	 endothelial-specific	 inactivation	 of	 FAK-Y861	
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phosphorylation	 has	 no	 impact	 on	 combined	 VEGF+ANG2-triggered	
angiogenesis.	
Results	 from	VEGF	 group	were	 compared	 to	 results	 from	ANG2+VEGF	
group,	 and	 this	 comparison	 showed	 that	 addition	 of	 ANG2	did	 not	 lead	 to	 an	
increase	in	the	number	of	sprouting	microvessels	per	aortic	ring.	This	indicates	
that	 in	 this	 experimental	 setting	 ANG2	 does	 not	 have	 a	 cumulative	 pro-
angiogenic	 effect.	 Noteworthy	 is	 the	 fact	 that	 ANG2	 does	 not	 have	 an	 anti-
angiogenic	effect	either.	
These	 results	 do	 not	 recapitulate	 the	 data	 obtained	 with	 the	 sponge	







Several	 in	 vivo	 models	 and	 protocols	 are	 available	 to	 study	 the	 link	
between	FAK-mutated	endothelial	cells	and	the	immune	cells.	One	way	to	study	
this	interaction	is	to	determine	whether	FAK-mutated	endothelial	cells	produce	
and	 secrete	 a	 different	 panel	 of	 cytokines	 that	 will	 then	 differentially	 attract	









Figure	 3.27:	 Endothelial	 specific	 FAK-Y861F	 mutation	 does	 not	 affect	
VEGF-driven	 sprouting	 angiogenesis,	 either	 in	 the	 presence,	 or	 in	 the	
absence	of	Ang2.	
Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice	 were	 given	 tamoxifen	 5	 days	 prior	 to	





from	 Cre-pos;	 FAK-Y861FKI	mice	when	 comparing	 to	 VEGF-treated	 rings	 from	 Cre-neg;	 FAK-
Y861FKI,	 indicating	that	FAK-Y861	phosphorylation	 in	endothelial	cells	does	not	 impair	VEGF-
driven	sprouting	angiogenesis.	Ang2	alone	did	not	act	as	a	pro-angiogenic	growth	factor	neither	
in	 rings	 from	Cre-neg;	FAK-Y861FKI	mice,	nor	 in	rings	 from	Cre-pos;	FAK-Y861FKI	mice.	When	
Ang2	was	 combined	with	 VEGF,	 sprouting	 angiogenesis	 equally	 triggered	 in	 rings	 from	 both	
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neg;	 FAK-WTKI,	 Cre-pos;	 FAK-WTKI,	 Cre-neg;	 FAK-Y397FKI,	 Cre-pos;	 FAK-
Y397FKI,	 Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice)	 and	 the	
induction	 of	 the	 chFAK-myc-tagged	 gene/protein	 and	 deletion	 of	 the	
endogenous	mouseFAK	gene/protein	was	confirmed	by	RT-qPCR	and	Western	
blotting	 in	 the	 Cre-pos	 cell	 lines	 as	 presented	 at	 the	 beginning	 of	 the	Results	
chapter	(Figure	3.1	D	and	E)1.	
Our	 laboratory	 has	 shown	 previously	 that	 loss	 of	 endothelial	 FAK	 can	
alter	cytokine	production	and	affect	angiocrine	signalling	(Tavora,	2014b).	Here	
I	sought	to	ask	whether	endothelial	FAK-Y397F	and	FAK-Y861F	mutations	have	





performed	 according	 to	 the	 manufacturer’s	 instructions	 using	 the	 previously	
prepared	 lysates	 to	determine	whether	cytokine	production	was	differentially	
modulated	 in	 FAK-Y397F	and	FAK-Y861F	mutated	 endothelial	 cells	 or	 if	 both	
mutations	affected	the	cytokine	profile	in	a	similar	way.	
																																																								
1	Cre-neg;	 FAK-WTKI	 and	Cre-pos;	 FAK-WTKI	 cell	 lines	were	 isolated	 and	 immortalized	 by	Dr.	










4.1. Validation	 of	 the	 KO/KI	 system	 for	 in	 vitro	 cytokine	
arrays	
	 Firstly	 the	 cytokine	 profile	was	 compared	 between	 Cre-neg;	 FAK-WTKI	
and	Cre-pos;	FAK-WTKI	and	no	difference	was	observed	between	these	two	cell	
lines,	 as	 shown	 on	 the	 cytokine	 dot-blot	 presented	 in	 Figure	 3.28.	 A	 few	
cytokines	 were	 produced	 in	 large	 quantities	 and	 could	 be	 detected	 after	 30	
seconds	 of	 exposure	 (sICAM-1	 and	 CCL2)	 or	 after	 5	minutes	 of	 exposure	 (M-
CSF,	TIMP-1,	and	TNF-alpha);	therefore,	for	these	cytokines	the	measurements	
were	taken	at	the	cited	exposure	times.	For	the	rest	of	cytokines,	measurements	
were	 taken	 after	 30	 minutes	 of	 exposure	 and	 the	 Cre-pos/Cre	 neg	 ratio	 is	
presented	 for	 all	 the	 cytokines	 in	 Figure	 3.28.	 Apart	 from	 the	 already	 cited	
cytokines	 that	 could	 be	 detected	 after	 short	 exposure	 times,	 very	 few	 other	
cytokines	 could	be	detected	 after	 30	minutes	 exposure	 in	 both	Cre-neg;	 FAK-
WTKI	and	Cre-pos;	FAK-WTKI	cell	lines,	indicating	that	Cre-neg	control	and	Cre-






4.2. Endothelial-specific	FAK-Y397F	mutation	 leads	 to	an	
increase	of	a	limited	number	of	cytokines	
The	cytokine	 level	 in	Cre	pos;	FAK-Y397FKI	was	normalised	to	Cre	neg;	





their	 level	 increased	more	 than	15-	and	up	to	25-fold	 in	 the	presence	of	FAK-
Y397F	mutation,	 but	 the	 biological	 reference	 of	 these	 results	will	 need	 to	 be	
confirmed	 with	 biological	 repeats	 or	 by	 exploring	 these	 targets	 using	 other	
techniques.	
	
4.3. Endothelial-specific	FAK-Y861F	mutation	 leads	 to	an	
increase	of	a	substantial	number	of	cytokines	
	
In	 a	 similar	 way	 the	 cytokine	 level	 in	 Cre-pos;	 FAK-Y861FKI	 was	
normalised	 to	 Cre-neg;	 FAK-Y861FKI	 and	 the	 fold-increase	 was	 used	 to	
determine	 which	 cytokines	 were	 more	 abundant	 in	 FAK-Y861F	 mutated	




1F1	 and	CCL2	were	more	 than	 100-fold,	 600-fold,	 and	 respectively	 1150-fold	
more	 abundant	 in	 endothelial	 cells	 bearing	 the	 FAK-Y861F	 mutation.	 These	
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results	 highlight	 the	 potency	 of	 FAK-Y861F	mutation	 to	 increase	 the	 level	 of	
cytokine	 production	 to	 a	 wider	 extend	 than	 the	 FAK-Y397F	 mutation,	 in	







Figure	 3.28:	 Endothelial	 cells	 isolated	 from	 Cre-neg;	 FAK-WTKI	 and	 Cre-
pos;	FAK-WTKI	mice	present	with	a	similar	cytokine	profile	in	vitro	
Endothelial	cells	were	isolated	from	Cre-neg;	FAK-WTKI	and	Cre-pos;	FAK-WTKI	mice,	plated	in	6	
cm	dishes	 in	duplicates,	 left	 to	grow	overnight	and	 lysed.	Protein	 concentration	was	adjusted	
amongst	 the	cell	 lysates	and	cell	 lysates	were	subsequently	used	 to	perform	a	cytokine	array,	
according	 to	 the	manufacturer’s	 instructions.	 Both	 duplicates	were	 used	 and	were	 incubated	
with	a	membrane	each.	Pictures	 from	one	of	each	duplicate	after	30	minutes	of	exposure	per	
genotype	 are	 shown.	 CXCL12,	 sICAM-1,	 CCL2,	 M-CSF	 and	 TNF-alpha	 were	 produced	 by	
endothelial	cells	of	both	genotypes.	Each	membrane	contains	two	dots	per	cytokine;	therefore	

















































































































































Figure	 3.29:	 Endothelial	 cells	 isolated	 from	 Cre-pos;	 FAK-Y397FKI	 mice	
produce	particularly	high	levels	of	CCL1	and	CCL2	cytokines	in	vitro	
Endothelial	 cells	 were	 isolated	 from	 Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	 mice,	
plated	in	6	cm	dishes	in	duplicates,	left	to	grow	overnight	and	lysed.	Protein	concentration	was	
adjusted	amongst	the	cell	lysates	and	cell	lysates	were	subsequently	used	to	perform	a	cytokine	
array,	 according	 to	 the	 manufacturer’s	 instructions.	 Both	 duplicates	 were	 used	 and	 were	
incubated	with	 a	membrane	 each.	 Pictures	 from	one	 of	 each	 duplicate	 per	 genotype	 after	 30	
minutes	of	exposure	are	shown.	Each	membrane	contains	two	dots	per	cytokine;	therefore	four	
measurements	 were	 available	 per	 cytokine	 and	 per	 genotype.	 The	 four	 measurements	 were	












































































































































Figure	 3.30:	 Endothelial	 cells	 isolated	 from	 Cre-pos;	 FAK-Y861FKI	 mice	
produce	particularly	high	 levels	of	 several	 cytokines,	 including	CCL2,	 IL-
1F1	and	CCL4	in	vitro	
Endothelial	 cells	 were	 isolated	 from	 Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice,	
plated	in	6	cm	dishes	in	duplicates,	left	to	grow	overnight	and	lysed.	Protein	concentration	was	
adjusted	amongst	the	cell	lysates	and	cell	lysates	were	subsequently	used	to	perform	a	cytokine	
array,	 according	 to	 the	 manufacturer’s	 instructions.	 Both	 duplicates	 were	 used	 and	 were	
incubated	with	 a	membrane	 each.	 Pictures	 from	one	 of	 each	 duplicate	 per	 genotype	 after	 30	
minutes	of	exposure	are	shown.	Each	membrane	contains	two	dots	per	cytokine;	therefore	four	
measurements	 were	 available	 per	 cytokine	 and	 per	 genotype.	 The	 four	 measurements	 were	
averaged	and	 the	Cre-pos/Cre-neg	ratio	was	calculated	and	 is	presented	as	 fold-increase.	The	















































































































































Table	 3.2	 presents	 the	 previously	 cited	 cytokines’	 fold-increase	 in	 the	
FAK-Y397F	and	FAK-Y861F	mutated	endothelial	cells	and	highlights	that	CCL2	
is	the	strongest	up-regulated	cytokine	for	both	mutations.	CCL2	was	detected	in	
Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	 endothelial	 cells	 after	 very	 short	
exposure	 times	 and	 is	 therefore	 a	 cytokine	 that	 is	 constitutively	 produced	 by	







CCL2 341 1191 
IL-1F1 1 628 
CCL4 -11 109 
IL-1F3 2 70 
IL-13 2 65 
IL-7 22 54 
IL-16 6 48 
IL-17 5 42 
IL-1F2 12 30 
IL-2 2 26 
IL-23 3 21 
CXCL12 2 19 
IL-12 p70 0.8 19 
IL-10 21 14 
CCL11 19 9 























Summary:	 Cytokine	 production	 by	 FAK-Y397F	 and	 FAK-Y861F	 mutated	
endothelial	cells	in	vitro	
These	 preliminary	 results	 show	 that	 FAK-Y397F	 mutated	 endothelial	
cells	 are	 able	 to	 up-regulate	 only	 a	 limited	 number	 of	 the	 studied	 cytokines,	
such	as	CCL11,	 IL-10,	CCL1	and	CCL2.	These	cytokines	are	specific	 to	Cre-pos;	
FAK-Y397FKI	 endothelial	 cells,	 with	 the	 exception	 of	 CCL2,	 which	 is	 also	 up-
regulated	 in	 Cre-pos;	 FAK-Y861FKI	 endothelial	 cells.	 FAK-Y861F	 mutated	




Whether	 FAK-Y397F	 and	FAK-Y861F	mutated	 tumour	 endothelial	 cells	
are	 up-regulating	 the	 same	 cytokines	 in	 vivo	 as	 the	 ones	 highlighted	 using	
endothelial	 cells	 in	 vitro	 and	 whether	 differential	 cytokine	 up-regulation	 in	
FAK-Y397F	 and	 FAK-Y861F	 mutated	 endothelial	 cells	 can	 explain	 the	









Focal	 adhesion	 kinase	 (FAK)	 is	 a	 protein	 tyrosine	 kinase,	 found	 in	 the	
cell	cytoplasm,	that	is	expressed	ubiquitously.	It	is	activated	and	overexpressed	
in	many	 solid	 cancers	 at	 advanced	 stages.	 FAK	 is	 known	 to	 promote	 tumour	
progression	 and	 metastasis	 through	 effects	 within	 the	 malignant	 cell	
compartment,	as	well	as	within	the	stromal	cell	compartment	(Gabarra-Niecko,	
2003).	FAK	controls	cell	migration,	cell	survival	and	gene	expression.	Within	the	
tumour	microenvironment	FAK	 is	 a	multifunctional	 regulator	 of	 cell	 signaling	
(Parsons,	2003;	Zhao	and	Guan,	2009;	Schaller,	2010;	Lechertier	and	Hodivala-
Dilke,	2012;	Sulzmaier,	Jean	and	Schlaepfer,	2014).	In	many	tumour	types,	FAK	
promotes	 cell	 motility,	 survival	 and	 proliferation	 through	 both	 kinase-
dependent	 and	 kinase-independent	 mechanisms	 and	 in	 the	 past	 few	 years,	




in	 particular	 how	 its	 phosphorylation	 sites	 regulate	 tumour	 angiogenesis,	 is	
poorly	understood.	Although	many	studies	in	vitro	have	demonstrated	roles	for	
tyrosine	 phosphorylation	 sites	 of	 FAK	 in	 cell	 behavior	 in	 culture	 (Brunton,	
2005;	Serrels,	2012),	almost	nothing	is	known	about	the	role	of	FAK-Y397	and	
FAK-Y861	phosphorylation	in	endothelial	cells	in	vivo.	Here	I	present	data	that	I	
have	 accumulated	 during	 my	 PhD	 that	 shows,	 for	 the	 first	 time,	 that	 the	
unphosphorylatable	 mutant	 of	 FAK-Y397F	 is	 sufficient	 to	 affect	 tumour	
angiogenesis	whereas	the	unphosphorylatable	mutant	of	FAK-Y861F	has	much	
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less	effect.	The	data	 from	my	 thesis	demonstrate	 that	by	making	novel	 in	vivo	
models	 of	 mutant	 FAK	we	 can	 start	 to	 really	 understand	 how	 FAK	 regulates	
tumour	angiogenesis	in	vivo.		
Phosphorylation	 of	 FAK-Y397	 allows	 Src	 to	 bind	 FAK	 via	 the	 revealed	
SH2-binding	site.	This	 initiates	Src	to	transphosphorylate	FAK	on	a	number	of	
tyrosine	 residues,	 including	 Y861.	 FAK–Y861	 phosphorylation	 stimulates	
p130Cas	 binding,	 thus	 activating	 downstream	 PI3-kinase	 signaling	 (Mitra,	
2005;	 Lechertier	 and	 Hodivala-Dilke,	 2012;	 Schlaepfer	 2014).	 Although	 FAK	
signaling	 appears	 to	 be	 straight-forward,	 some	 studies	 have	 shown	 that	 FAK	
can	be	upstream	of	unexpected	pathways.	For	example,	VEGF-stimulation	 can	
induce	a	Src-dependent	increase	in	Y861	phosphorlyation,	without	an	increase	
in	 Y397	 phosphorylation	 (Abu-Ghazaleh,	 2001).	 The	 deletion	 or	 depletion	 of	







Schmidt,	 2013)	 and	 Tie2-CreERT	 (Braren,	 2006)	 and	 all	 show	 an	 impact	 on	
neovascularization.	 These	 data	 indicate	 that	 FAK	 is	 involved	 in	 angiogenesis,	
but	 how	 different	 tyrosine	 motifs	 of	 FAK	 regulate	 processes	 in	 vivo	 is	 still	
unexplained.	One	of	the	first	FAK-point	mutant	knock-in	mouse	models	was	the	
FAK-kinase	dead	knockin,	generated	using	SCL-CreERT–driven	induction	of	the	
mutant	 FAK	 on	 one	 allele	 of	 FAK	 null	 mice	 (Zhao,	 2010;	 Chen,	 2012).	 This	
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strategy	induces	the	one	copy	of	the	mutant	FAK-kinase	dead	as	a	hemizygous	
and	 controls	were	hemizygous	wild	 types.	Our	 laboratory	has	 shown	 that	 the	
global	 FAK-heterozygous	 mice	 display	 enhanced	 tumour	 growth	 and	
angiogenesis	and	thus	these	data	suggest	that	half	the	expression	levels	of	FAK	
can	give	an	elevated	tumour	angiogenic	response	(Kostourou,	2013).	
We	 were	 particularly	 interested	 in	 examining	 the	 role	 of	
phosphorylation	 of	 Y397	 and	 Y861	 specifically	 in	 vivo.	 But	 given	 that	
hemizygous	 FAK-mutants	might	 lead	 results	 different	 from	 homozygous	 FAK	
mutants,	we	 used	mice	where	 FAK	 could	 be	 knocked-out	 on	 both	 alleles	 and	
mutated	 FAK	 knocked-in	 on	 both	 alleles	 as	 well.	 Therefore	 we	 developed	 a	
series	of	endothelial	cell-specific	PDGFb-CreERT2	inducible	mutant	FAK-knockin	
mice	 which,	 when	 crossed	 with	 FAK-floxed	 mice,	 generate	 mice	 where	
endogenous	FAK	is	knocked-out	and	mutant	FAK,	either	WT,	Y397F	or	Y861F,	is	
simultaneously	 knocked-in	 driven	 by	 the	 ROSA	 26	 promoter,	 and	 where	 the	
knocked-in	 FAK	 is	 expressed	 in	 a	 homozygous	 and	 not	 hemizygous	 fashion	
(Claxton,	2008;	Tavora,	2014a).	
	
1. Role	 of	 endothelial	 specific	 FAK-Y397	 and	 FAK-Y861	 phos-
phorylation	in	tumour	growth	and	angiogenesis	in	vivo	
To	 study	 the	 role	 of	 endothelial	 specific	 FAK-Y397	 and	 FAK-Y861	
phosphorylation	 in	 tumour	 growth	 and	 angiogenesis	 in	 vivo,	 Cre-pos;	 FAK-
Y397FKI	 and	 Cre-neg;	 FAK-Y397FKI;	 Cre-pos;	 FAK-Y861FKI	 and	 Cre-neg;	 FAK-
Y861FKI	mice	were	given	melanoma	(B16F0)	or	 lung	 carcinoma	(CMT19T	or	
LLC)	 subcutaneous	 tumour	 cell	 injections.	 Subsequent	 tumour	 growth	 and	
angiogenesis	 was	 examined.	 The	 endothelial-specific	 FAK-Y397F	 mutation	
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resulted	 in	 delayed	 angiogenesis	 for	 all	 the	 studied	 subcutaneous	 models,	
suggesting	 that	 FAK-Y397	 autophosphorylation	 in	 endothelial	 cells	 is	
essential	 for	 tumour	 angiogenesis.	Previous	work	on	FAK-kinase	dead	mutant	
mice	actually	showed	no	difference	in	tumour	angiogenesis	(Chen,	2012;	Jean,	




apparent	 discrepancy	 is	 that	 in	 my	 study	 I	 have	 induced	 the	 endothelial	
mutation	 before	 the	 injection	 of	 tumour	 cells,	 where	 as	 in	 the	 kinase	 dead	
studies	 the	 FAK-kinase	dead	mutation	was	 induced	 after	 tumour	 growth	 and	
presumably	angiogenesis	had	been	initiated	(Jean,	2014).	This	implies	that	loss	
of	 Y397	 phosphorylation	 may	 be	 important	 in	 the	 initiation	 of	 angiogenesis	
rather	 than	 the	maintenance	of	established	vessels.	To	 test	 this	hypothesis,	 it	
could	 be	 possible	 to	 perform	 tumour	 growth	 experiments	 and	 to	 administer	
tamoxifen	 after	 tumour	 cell	 injection.	 If	 tumour	 growth	 is	 not	 impaired,	 than	





deletion	 of	 Y397	 at	 exon	 15	 (Corsi,	 2009).	 This	 exon	 15	 deletion	 mutation	
totally	removes	the	Y397	motif	 from	FAK,	maintains	kinase	activity	but	was	a	
constitutive,	 global	 mutant	 that	 caused	 embryonic	 lethality	 at	 around	 E12.5	
onwards.	These	FAK	 exon	15	deleted	 embryos	displayed	hemorrhage,	edema,	
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delayed	 artery	 formation	 and	 various	 vascular	 remodeling	 defects	
demonstrating	 that	 FAK-Y397	 is	 required	 for	 normal	 development	 (Corsi,	
2009).	Although	this	was	not	an	endothelial-specific	knockout	 it	does	suggest	
that	Y397	 is	 required	 for	 at	 least	 some	 stages	of	developmental	 angiogenesis	
and	 in	this	regard	correlates	with	our	tumour	angiogenesis	defect	 in	our	Cre-
pos;	 FAK-Y397FKI	 mice.	 Our	 data	 suggest	 that	 targeting	 endothelial-specific	
FAK-Y397	 phosphorylation	 is	 sufficient	 to	 affect	 tumour	 growth	 and	may	 be	
worth	 pursuing	 clinically.	 Several	 papers	 have	 demonstrated	 that	 the	
scaffolding	 function	 of	 Y397	 is	 important	 in	 FAK	 function	 and	 that	 inhibiting	
this	scaffold	function	could	provide	pharmacologically	relevant	agents	that	may	
indeed	 be	 more	 effective	 than	 inhibiting	 FAK-kinase	 function	 alone	 (Cance,	
2013).	 Inhibitors	 of	 scaffold	 function	 to	 Y397	 have	 been	 tested	 and	 do	 show	
promise,	 but	 they	 are	 not	 specific	 for	 FAK-Y397	 and	 thus	 there	 is	 some	
resistance	in	the	field	to	take	these	into	general	clinical	practice.	
As	 tumour	 blood	 vessels	 develop	 they	 go	 through	 various	 stages	 of	
morphological	changes	that	affect	their	function.	Tumour	blood	vessels	need	to	
be	well	perfused	but	many	reports	have	highlighted	that	their	perfusion	can	be	
erratic	 and	 that	 this	 can	 affect	 tumour	 growth	 (Carmeliet,	 2011).	 In	 addition	
tumour	 blood	 vessels	 are	 notoriously	 leaky	 with	 large	 intercellular	 gaps	
(Carmeliet,	 2011).	 Lastly,	 supporting	 cell	 pericyte	 coverage	 can	 affect	 the	
stability	of	 the	vessels	and	their	diameter	 that	 in-turn	affect	 flow	through	the	
vessel	 (Carmeliet,	 2011).	 In	 global	 FAK	 heterozygous	mice	 in	 addition	 to	 the	
increased	 tumour	 vascularization,	 increased	 tumour	 blood	 vessel	 perfusion	
and	increased	associated	VEGF-induced	pAkt:Akt	signaling	with	an	rebalance	in	
phosphorylation	 at	 Y397	 vs	 Y861	 residues	was	 reported	 indicating	 that	 FAK	
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can	 affect	 these	 parameters	 (Kostourou,	 2013).	 In	 contrast,	 in	 PDGFb-
CreERT;FAKfl/fl	mice,	in	addition	to	reduced	tumour	blood	vessel	density,	there	
was	 an	 associated	 increase	 in	 tumour	 hypoxia	 and	 decreased	 VEGF-induced	
pAkt;Akt	 ration	 (Tavora,	 2010).	 Thus	 I	 investigated	 these	 features	 in	 the	
tumour	 blood	 vessels	 in	 Cre-pos;	 FAK-Y397FKI	 mutant	 mice.	 Tumour	 blood	
vessel	perfusion,	tumour	blood	vessel	perimeter,	Hoechst	leakage	and	pericyte	
coverage	 were	 unaffected	 by	 the	 endothelial	 specific	 FAK-Y397F	 mutation.	




pos;	 FAK-Y397FKI	 mice	 was	 accompanied	 by	 delayed	 tumour	 growth.	 It	 is	
therefore	 likely	 that	 the	 delayed	 tumour	 growth	 is	 a	 consequence	of	delayed	
tumour	angiogenesis	and	that	endothelial	specific	FAK-Y397F	mutation	affects	
tumour	 growth	 by	 quantitatively,	 rather	 that	 qualitatively,	 affecting	 tumour	
endothelium.	 Two	 supplementary	 observations	 support	 this	 hypothesis:	
delayed	 tumour	 angiogenesis	 at	 an	 early	 time	 point	 (Day	 8)	 and	 increased	
tumour	 hypoxia	 (Day	 17).	 Indeed,	 the	 delayed	 tumour	 angiogenesis	 was	
observed	 in	 8-day	 old	 tumours	 before	 the	difference	 in	 tumour	 volumes	was	
apparent,	suggesting	that	delay	in	tumour	angiogenesis	precedes,	if	not	causes,	
delayed	 tumour	 growth.	 The	 endothelial	 cell-specific	 FAK-Y397F	 mutation	
leads	 to	 increased	 tumour	 hypoxia	 in	 17-day	 old	 tumours,	 indicating	 that	
tumour	 cells	 lack	 oxygen	 in	 tumours	 irrigated	 by	 a	 reduced	 number	 of	 FAK-
Y397F	mutated	blood	vessels.	This	evidence	suggests	strongly	that	FAK-Y397F	




In	 contrast	 to	 these	 findings,	 the	 growth	 of	 LLC	 carcinoma	 tumours	
was	not	delayed	by	the	endothelial-specific	FAK-Y397F	mutation.	Interestingly	
this	 lack	of	a	tumour	growth	phenotype	was	actually	accompanied	by	reduced	
tumour	 angiogenesis	 in	 the	Cre-pos;	 FAK-Y397FKI	mice.	This	 suggests	 that	 the	
previously	described	hypothesis/conclusion	–	that	delayed	tumour	growth	is	a	
consequence	 of	 delayed	 tumour	 angiogenesis	 –	 does	 not	 apply	 to	 the	 LLC	
tumour	model,	where	the	delayed	tumour	angiogenesis	observed	in	24-day	old	
tumours	does	not	 affect	 tumour	 volumes	 and	 raises	 the	 question	 about	 the	
differences	that	exist	between	the	three	tumour	models,	about	the	parameters	
that	drive/allow	their	growth	and	about	the	possibility	that	LLC	carcinoma	cells	
might	 require	 less	 oxygen.	 Tumour	 hypoxia	 has	 not	 yet	 been	 assessed	 in	 LLC	
tumours	 and	 it	 will	 be	 important	 to	 determine	 if	 decreased	 tumour	
angiogenesis	 leads	 to	 increased	 tumour	 hypoxia	 in	 a	 situation	where	 tumour	
volumes	are	not	affected	by	the	endothelial	specific	FAK-Y397F	mutation.	Some	
studies	have	highlighted	 that	 tumour	growth	and	angiogenesis	are	not	always	
related	 (Adighibe,	 2016).	 Indeed	 knowing	 that	 different	 tumour	 cell	 lines	 can	
produce	 different	 amounts	 and	 signatures	 of	 growth	 factors	 may	 well	 be	 a	
reason	why	 the	 LLC	 tumour	 growth	was	 not	 affected	 in	 the	 same	way	 as	 the	
B16F0	 or	 CMT19T	 tumour	 growth	 in	 the	 Cre-pos;	 FAK-Y397FKI	 mice	 (Zhang,	
2008).	
Indeed,	the	results	obtained	for	LLC	tumour	model	in	the	Cre-pos;	FAK-	
Y397FKI	 mice	 raise	 several	 questions.	 For	 example,	 is	 the	 inefficiency	 of	 the	
anti-angiogenic	 affect	 of	 the	 endothelial	 FAK-Y397F	 mutation	 on	 tumour	
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volumes	specific	to	the	LLC	tumour	model?	And,	in	the	B16F0	and	the	CMT19T	




The	 observation	 that	 the	 three	 studied	 tumour	 models	 do	 not	
present	 the	 same	 phenotype	 for	 the	 same	 endothelial	 FAK-Y397F	 mutation	
could	be	indicative	that	the	anti-angiogenic	effect	of	the	mutation	might	not	be	
the	 cause	 for	 delayed	 tumour	 growth.	 It	 raises	 the	 notion	 that	 there	 is	 a	
possibility	that	even	for	the	B16F0	and	CMT19T	tumour	models,	 the	observed	
effect	 on	 tumour	 volumes,	 might	 not	 be	 completely	 attributable	 to	 reduced	
vasculature.	 Although	 against	 the	 dogma,	 this	 idea	 should	 not	 be	 ruled	 out.	
Indeed	 the	 endothelial	 FAK-Y397F	mutation	might	 have	 a	 paracrine	 effect	 on	
other	stromal	elements	such	as	immune	infiltrate	or	directly	tumour	cells,	that	
collectively	affect	tumour	growth.	I	will	come	back	to	this	idea	nearer	the	end	of	
this	 chapter	 but	 others	 have	 shown	 that	 paracrine	 factors	 generated	 by	
endothelial	 cells	 can	affect	 immune	cell	 infiltrate	and	 tumour	cells	directly,	 so	
this	may	well	be	an	interesting	idea	to	follow	up	in	future	experiments.	
The	observation	that	delayed	angiogenesis	does	not	necessarily	lead	to	
delayed	 tumour	 growth	 is	 either	 restricted	 to	 FAK-Y397F	 mutated	
endothelium,	 or	 to	 the	 LLC	 tumour	 model.	 Indeed,	 delayed	 tumour	
angiogenesis	was	also	observed	in	7-	and	17-day	old	B16F0	tumours	growth	in	
Cre-pos;	 FAK-Y861FKI	 mice.	 Nevertheless,	 quantification	 of	 tumour	
angiogenesis	 at	 Day	 21	 shows	 that	 there	 is	 no	 difference	 in	 tumour	
angiogenesis	 at	 this	 latest	 time	 point.	 Previous	 work	 has	 suggested	 that	
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phosphorylation	 of	 the	 FAK-Y861	 motif	 is	 especially	 important	 in	 VEGF-
induced	 angiogenic	processes	 in	vitro	 (Abu-Gazaleh,	 2001).	 Indeed	 this	 study	
suggested	that	phosphorylation	at	FAK-Y861	is	likely	to	play	a	more	important	
role	 than	 phosphorylation	 at	 FAK-Y397	 in	 the	 regulation	 of	 endothelial	 cell	
migration	and	apoptosis	(Abu-Gazaleh,	2001).	My	data	suggest	that	in	vivo,	it	is	
possible	 that	 the	 inactivation	 of	 FAK-Y861	 phosphorylation	 affects	 the	
initiation	 of	 tumour	 angiogenesis,	 but	 becomes	 dispensable	 for	 tumour	
endothelium	 remodeling,	 thus	 restoring	 blood	 vessel	 density	 at	 time	 points	
after	day	21	of	tumour	growth.	
Parameters	 of	 tumour	 blood	 vessel	 function	 and	 integrity	 were	 also	
analysed	 in	 the	B16F0	 tumours	 grown	 in	 Cre-pos;	 FAK-Y861FKI	 mice.	 For	 all	
the	parameters	tested	including	tumour	blood	vessel	perfusion,	tumour	blood	
vessel	perimeter,	Hoechst	leakage	and	pericyte	coverage	and	no	difference	was	
observed	 between	 Cre-pos;	 FAK-Y861FKI	 and	 Cre-neg;	 FAK-Y861FKI	 mice.	
Importantly,	 tumour	 hypoxia	was	 not	 increased	 in	 B16F0	 tumours	 grown	 in	




the	 relationship	 between	 the	 initially	 impaired	 tumour	 angiogenesis	 and	 the	
hypoxic	 tumour	tissues.	 It	should	be	noted	that	 I	analysed	tumour	hypoxia	at	
Day	21,	when	the	FAK-Y861F	tumour	angiogenesis	defect	was	already	resolved	
and	 blood	 vessel	 density	was	 not	 reduced	 anymore.	 In	 future	 experiments	 it	
would	 be	 important	 to	 examine	 tumour	 hypoxia	 at	 earlier	 stage	 tumours	 in	
Cre-pos;	FAK-Y861FKI	mice,	ie.,	when	the	blood	vessel	density	is	low,	and	see	if	
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this	 correlates	 with	 changes	 in	 hypoxia.	 Although	 it	 is	 unclear	 if	 similar	
scenarios	 have	 been	 discovered	 previously,	 if	 the	 endothelial	 specific	 FAK-
Y861F	 mutation	 fails	 to	 induce	 tumour	 hypoxia	 in	 early	 time	 points	 when	
delayed	tumour	angiogenesis	is	observed,	then	perhaps	the	inability	to	trigger	
tumour	 hypoxia	 might	 explain	 why	 this	 mutation	 does	 not	 lead	 to	 impaired	
tumour	 growth.	 On	 the	 other	 hand,	 if	 hypoxia	 were	 affected	 in	 early	 time	
points	 and	 then	 overcome,	 as	 delayed	 angiogenesis	 is,	 then	 this	 would	
highlight	 the	 ability	 of	 FAK-Y861F	 mutation	 to	 overcome	 not	 only	 delayed	
tumour	 angiogenesis	 but	 also	 restore	 the	 levels	 of	 tumour	 cell	 hypoxia.	
Determining	 the	 similarities	 and	 the	 differences	 between	 the	 three	 tumour	
types	 in	 terms	 of	 tumour	 cell	 hypoxia	 as	 a	 result	 of	 endothelial	 FAK-Y861F	
mutation	will	provide	clues	into	potential	signalling	mechanisms.	
In	 a	 nutshell,	 the	 two	 FAK	mutations	 in	 endothelial	 cells	 present	with	
different	 hypoxia	 phenotype,	more	precisely	 endothelial	 FAK-Y397F	mutation	
increases	 tumour	 cell	 hypoxia,	 whereas	 endothelial	 FAK-Y861F	 mutation	
does	not	have	an	effect	on	tumour	hypoxia	(at	 the	studied	time	point).	This	 is	
indicative	 that	 two	 phosphorylation	 sites	 of	 the	 same	 protein	 in	 endothelial	
cells	 might	 be	 able	 to	 differentially	 regulate	 signaling	 pathways	 leading	 to	
tumour	 cell	 hypoxia.	 This	 could	 be	 due	 to	 the	 differential	 ability	 of	 these	
endothelial	 mutations	 to	 affect	 tumour	 angiogenesis,	 but	 also	 the	 possibility	
that	 secreted	 factors,	 controlled	 by	 the	 mutated	 endothelial	 cells	 or	 other	
elements	of	the	stroma	could	play	a	role.	
Permeability	 through	blood	vessels	 is	 controlled	at	 endothelial	 cell-cell	
junctions.	VE-cadherin	is	one	of	the	major	cell-cell	endothelial-specific	adhesion	




directly	 involved	 in	vessel	permeability	 (Arnold,	2013).	 In	endothelial-specific	




FAK-kinase	 regulation	 of	 VE-cadherin	 activity	 (Chen,	 2012).	 Additionally	
tumour	 metastasis	 was	 shown	 to	 be	 reduced	 in	 EC-FAK-kinase	 dead	 mice	
suggesting	 that	 FAK	 inhibition	 using	 FAK-kinase-inhibitors	 may	 be	 a	 good	
strategy	 for	 controlling	 tumour	 metastasis	 (Jean,	 2014).	 In	 these	 papers,	 the	
authors	show	that	the	endothelial	cells	from	the	EC-FAK-kinase	dead	mice	have	
a	 reduction	 in	 levels	 of	 FAK-Y397	 phosphorylation,	 implying	 that	
phosphorylation	 of	 Y397	maybe	 be	 involved	 in	 this	 process.	 In	 FAK	 exon	 15	









measure	 of	 leakage.	 I	 found	 that	 unphosphorylated	 endothelial-specific	 FAK-
Y397F	 or	 Y861F	 mutant	 mice	 had	 no	 apparent	 defect	 in	 tumour	 vascular	
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leakage.	 This	means	 that	 it	 is	 unlikely	 that	 phosphorylation	 at	 FAK-Y397	 and	
Y861	is	involved	in	tumour	vascular	leakage.	Although	the	different	methods	in	
measuring	tumour	vascular	were	employed	it	is	hard	to	imagine	that	this	could	
bias	 our	 results	 when	 we	 compare	 with	 previous	 studies.	 Importantly,	
understanding	 whether	 homozygous	 FAK-kinase	 dead	 mice	 show	 reduced	
tumour	vessel	leakage	would	be	important	to	determine	and	our	laboratory	has	
developed	 these	 mice	 for	 this	 purpose.	 In	 future	 experiments	 understanding	
whether	tumour	metastasis,	VE-Cadherin	expression	and	function	or	responses	
to	 VEGF-induced	 permeability	 are	 affected	 by	 endothelial-specific	 FAK-Y397F	
or	 endothelial-specific	 FAK-Y861F	mutations	would	 be	 of	 interest.	Metastasis	
could	 be	 investigated	 using	 the	 B16F10	 tumour	 model,	 that	 allows	 these	
particular	type	of	melanoma	cells	to	form	metastasis	in	the	lungs.	Alternatively,	
spontaneous	 tumour	models	 (such	 as	Rip-TAG	models)	 could	be	 crosses	with	
the	 KI	 colonies	 to	 look	 at	 the	 role	 of	 tumour	 angiogenesis	 in	 a	 more	
physiologically	relevant	metastasis	assay.	
	
2. Role	 of	 endothelial	 specific	 FAK-Y397	 and	 FAK-Y861	
phosphorylation	 in	 growth-factor	 induced	 angio-
genesis	in	vivo		
Several	 publications	 have	 demonstrated	 that	 tumour	 angiogenesis	 is	
governed	 by	 responses	 to	 tumour	 cell	 derived	 growth	 factors	 (Ziyad,	 2011;	
Gacche,	 2015;	 Yadav,	 2015).	 In	 endothelial	 cells	 isolated	 from	 tumours,	 the	
levels	 of	 FAK-Y397	 phosophorylation	 are	 elevated	 and	 have	 been	 linked,	




used	 previously	 to	 test	 whether	 specific	 growth	 factor	 induced	 angiogenesis	
was	 altered	 (Tavora,	 2010).	 In	 these	 studies	 both	 VEGF	 and	 bFGF	 induced	
angiogenesis	 was	 inhibited	 in	 ECFAK-null	 mice	 (Tavora,	 2010).	 In	 contrast	
VEGF	 induced	 angiogenesis	 was	 enhanced	 in	 global	 FAK	 heterozygous	 mice	
indicating	 that	 somehow,	 FAK	 could	 regulate	 specific	 growth	 factor	 induced	
angiogenic	 responses,	 in	 a	 dose	 dependent	 fashion,	 in	 a	 tumour-free	
environment	 (Kostourou,	 2013).	 However,	 understanding	 the	 role	 of	
phosphorylation	at	FAK-Y397	or	FAK-Y861	was	not	possible	 in	 these	mice.	 In	
order	 to	 test	 the	 effect	 of	 endothelial-specific	 FAK-Y397F	 and	 endothelial-
specific	FAK-Y861F	 in	growth	 factor	driven	angiogenesis	 in	vivo,	 and	because	
differential	 responses	 to	 tumours	 may	 reflect	 changes	 in	 the	 cocktail	 of	
growth	 factors	 generated	 from	different	 tumour	 cells,	 sponge	assay	 (an	 in	
vivo	 growth	 factor	 induced	 angiogenesis	 assay)	 was	 performed	 in	 our	
endothelial-specific	 FAK-Y397F	 and	 endothelial-specific	 FAK-Y861F	 mutant	
mice.	The	effects	of	these	mutations	on	VEGF,	PlGF,	bFGF	and	Ang2	stimulated	
angiogenesis	were	assessed.	
Endothelial	 specific	 FAK-Y397F	 mutation	 impairs	 microvessel	
infiltration	 in	 VEGF,	 PlGF	 and	 bFGF	 stimulated	 in	 vivo	 growth	 factor	 induced	
assays.	My	 results	 indicate	 that	 FAK-Y397	 auto-	 phosphorylation	 site	 plays	 a	
major	 role	 in	 all	 the	 studied	 growth	 factor	 initiated	 pathways.	 This	 is	 not	
surprising	 as	 this	 mutation	 presented	 with	 a	 strong	 tumour	 angiogenesis	
phenotype	in	all	the	studied	tumour	models.	
Interestingly,	 endothelial	 FAK-Y397F	 mutation	 also	 affected	
microvessel	 infiltration	 in	 PBS	 control	 sponges	 suggesting	 that	 this	 mutation	
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might	be	able	to	impair	angiogenesis	independently	of	the	growth	factor	that	is	
triggering	 it.	 Indeed,	 since	 FAK-deficiency	 has	 been	 related	 to	 an	 increase	 in	
endothelial	 cell	 apoptosis	 and	 decrease	 in	 proliferation	 (Tavora,	 2010)	
endothelial	 FAK-Y397F	mutation	may	 induce	 baseline	 changes	 in	 endothelial	
cell	 apoptosis	 which	 would	 affect	 the	 overall	 survival	 rate	 of	 the	 endothelial	
cells	and	this	independently	of	the	growth	factor	stimulation.	
This	 observation	 might	 be	 important	 for	 tumour	 models	 as	 well.	 For	
example,	when	anti-VEGF	antibodies	were	used	in	animal	models	of	pancreatic	
cancer,	 they	 showed	 a	 temporary	 reduction	 in	 tumour	 blood	 vessels	
(Casanovas,	2005).	Casanovas	et	al.	demonstrated	that	resistance	to	anti-VEGF	
therapy	 was	 enabled	 by	 compensatory	 mechanisms	 involving	 bFGF.	 Since	
both	 VEGF	 and	 bFGF	 signaling	 are	 reduced	 by	 the	 endothelial	 specific	 FAK-
Y397F	mutation,	 it	would	be	 interesting	 to	 investigate	 if	delayed	angiogenesis	
would	 be	 temporary	 or	 more	 long	 lasting	 in	 a	 similar	 model	 of	 pancreatic	
cancer.	
In	 contrast	 to	 the	 endothelial-specific	 FAK-Y397F	 mutation,	
endothelial	 specific	 FAK-Y861F	 mutant	 mice	 did	 not	 show	 changes	 in	
microvessel	 infiltration	 in	VEGF,	PlGF	and	bFGF	treated	sponges.	These	data	
indicate	that	phosphorylation	and	FAK-Y861	 is	 dispensable	 for	 angiogenesis	
in	 this	 experimental	 setting.	The	 finding	 that	FAK-Y861F	mutation	does	not	
affect	VEGF	signaling	is	surprising,	especially	since	previous	in	vitro	work	has	
shown	that	VEGF-stimulated	angiogenesis	 responses	may	act	predominantly	




mystery.	 It	must	be	noted	that	the	cited	study	was	conducted	 in	vitro	and	 in	
2D	culture	conditions	and	it	is	possible	that	the	difference	in	the	models	and	
approaches	(in	vitro	vs	 in	vivo/ex-vivo;	2D	model	vs	3D	model)	could	explain	
why	 the	 same	 results	 are	 not	 obtained.	 Nevertheless,	 in	 the	 area	 of	 cancer	
research	and	tumour	angiogenesis,	in	vivo	and	3D	models	are	mostly	relevant.	
	Microvessel	 infiltration	 in	 sponges	 and	 tumour	 angiogenesis	 can	be	
governed	 by	 different	mechanisms,	 and	 this	 is	 not	 only	 due	 to	 tumour	 cell	
presence,	 but	 also	 to	 tumour	 stroma,	 such	 as	 cancer	 associated	 fibroblasts	
and	tumour	infiltrated	immune	cells.	It	may	be	that	actually	what	governs	the	
role	of	FAK-Y861	phosphorylation	is	not	to	do	with	differential	growth	factor	
responses	 but	 differential	 responses	 to	 other	 components	 of	 the	 tumour	
microenvironment.	
In	my	growth	factor-induced	angiogenesis	assays	in	vivo,	Ang2	was	not	
able	 to	 trigger	 microvessel	 infiltration	 into	 the	 sponges	 implanted	 in	 Cre-
negative	control	mice	as	strikingly	as	VEGF	did.	This	 is	 in	 line	with	previous	
work,	 especially	 from	 Helmut	 Augustin	 lab	 that	 shows	 that	 Ang2	 needs	 to	
work	 in	 partnership	 with	 other	 growth	 factors	 to	 control	 endothelial	 cell	
behavior	 (Felcht,	 2012).	 Nevertheless	 when	 endothelial	 cells	 bear	 the	 FAK-
Y397F	 mutation	 microvessel	 infiltration	 into	 Ang2	 containing	 sponges	 is	
decreased.	 This	 might	 be	 due	 to	 the	 fact	 that	 in	 all	 conditions,	 including	
control	 conditions	 microvessel	 infiltration	 was	 decreased.	 However	
microvessel	 infiltration	was	 increased	upon	Ang2	 treatment	 in	 cells	bearing	
the	FAK-Y861F	mutation,	 indicating	 that	Ang2	 is	 sensed	as	a	pro-angiogenic	
factor	 by	 FAK-Y861F	 mutated	 endothelial	 cells.	 This	 is	 a	 very	 exciting	
observation	and	one	that	will	be	followed	up	in	future	experiments.	Ang2	has	
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been	 reported	 to	 be	 produced	 by	 endothelial	 cells	 (Fiedler,	 2004).	 Previous	
work	 showed	 an	 involvement	 of	 FAK-S910	 in	 Tie-2	 expressing	 endothelial	
cells	 (Felcht,	 2012).	 However	 it	 is	 not	 known	 to	 date	whether	 loss	 of	 FAK-
Y861	phosphorylation	could	affect	Ang2	production	that	 in-turn	could	affect	
different	 parameters	 of	 tumour	 cell	 growth,	 other	 tumour	 micro-
environmental	elements	and	endothelial	cell	behaviour.	Indeed	it	will	be	very	
interesting	to	understand	how	switching	to	a	non-phosphorylatable	version	of	
FAK-Y861	makes	 the	 endothelial	 cells	 responsive	 to	Ang2	 and	whether	 this	
effect	 is	 due	 to	 changes	 in	 Ang2	 receptor	 expression	 (Tie1	 and	 Tie2)	 or	
activity	 on	 these	 mutant	 endothelial	 cells.	 It	 would	 be	 of	 interest	 also	 to	
examine	whether	B16F0,	CMT19T	and	LLC	 tumour	cells	all	have	differential	
Ang2	expression	relative	to	other	growth	factors	and	how	the	balance	of	these	
growth	 factors	 might	 affect	 angiogenic	 responses	 in	 growth	 factor	 induced	
assays	in	vivo.	Another	aspect	to	consider	is	potential	changes	in	growth	factor	
receptors	 (VEGFR1,	 VEGFR2,	 FGFR2,	 etc)	 at	 the	 plasma	 membrane	 of	
endothelial	cells	due	to	FAK-Y397F	or	FAK-Y861F	mutations.		
Lastly,	it	is	clear	that	these	growth	factor	induced	angiogenesis	assays	
will	 induces	 changes	 cytokine	 production	 and	 in	 immune	 infiltrate	 into	
sponges	 that	may	 not	 reflect	 the	 cytokine	 and	 immune	 infiltrate	within	 the	
tumours	 and	 might	 complicate	 the	 interpretation	 of	 the	 results	 (Crusz	 and	




3. Role	 of	 endothelial	 specific	 FAK-Y397	 and	 FAK-Y861	
phosphorylation	 in	 growth-factor	 induced	 angio-
genesis	ex	vivo	
Sprouting	angiogenesis	was	next	studied	ex	vivo	using	the	aortic	rings	
assay	 (Baker,	 2011).	 This	 method	 is	 used	 extensively	 to	 examine	 growth	
factor	induced	angiogenic	responses	ex	vivo	(Baker,	2011).	Using	aortic	rings	
isolated	 from	 endothelial-specific	 WT,	 FAK-Y397F	 or	 FAK-Y	 861	 mice	 and	
their	 controls	 I	 studied	 ex	 vivo	 angiogenic	 responses	 to	 VEGF,	 Ang2	 or	 the	
combination	of	both	(VEGF+Ang2).	
As	 observed	 in	 the	 sponge	 assay	 and	 in	 line	 with	 tumour	
angiogenesis	 data,	 endothelial	 specific	 FAK-Y397F	 mutation	 impairs	 VEGF-
driven	 sprouting	 angiogenesis.	 Moreover	 Ang2	 does	 not	 act	 as	 a	 pro-
angiogenic	 growth	 factor	 on	 the	 FAK-Y397F	mutated	 sprouts.	 Nevertheless	






the	LLC	carcinoma	model.	 This	 suggests	 that	 there	might	 be	 a	 link	 between	
the	 milder	 LLC	 tumour	 growth	 phenotype	 in	 the	 endothelial-specific	 FAK-
Y397F	mice	and	the	ability	of	Ang2	to	partially	rescue	the	impaired	sprouting	
angiogenesis	 phenotype.	 This	 hypothesis	 could	 be	 investigated	 by	
determining	 if	LLC	 tumours	attract	a	different	Ang2-responsive	 immune	cell	
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obtained	 in	 the	 sponge	 assay.	 Ang2	 alone	 does	 not	 trigger	 angiogenesis	
either	in	control,	or	in	the	endothelial	FAK-Y861F	mutated	sprouts,	indicating	
that	in	this	experimental	setting	Ang2	does	not	act	as	a	pro-angiogenic	growth	
factor.	 When	 endothelial	 FAK-Y861F	 mutated	 sprouts	 are	 treated	 with	 the	
VEGF+Ang2	combination,	sprouting	angiogenesis	is	triggered	to	a	level	similar	
to	 the	 previously	 observed	 VEGF-driven	 sprouting	 angiogenesis.	 This	
indicates	that	Ang2	does	not	act	as	an	anti-angiogenic	growth	factor	either	in	
control,	 or	 in	 the	FAK-Y861F	mutated	endothelial	 cells,	 in	 this	 experimental	
setting.	
Overall	 the	 findings	 for	 the	 FAK-Y861F	 mutation	 indicate	 that	 Ang2	
does	not	 act	 as	 a	 pro-angiogenic	 factor	 in	 the	ex	vivo	aortic	 ring	 assay,	where	
immune	cells	do	not	play	a	role,	whereas	 it	can	be	sensed	as	a	pro-angiogenic	
factor	 by	 FAK-Y861F	 mutated	 endothelial	 cells	 in	 the	 in	 vivo	 sponge	 assay,	
where	immune	cells	could	potentially	infiltrate	the	sponges.	This	might	suggest	








(Lim,	 2012).	 In	 addition	 to	 its	 roles	 in	 tumour	 growth	 and	 angiogenesis	
initiation,	 endothelial-specific	 FAK	 has	 been	 shown	 to	 regulate	 cytokine	
production	 in	 response	 to	 DNA-damaging	 agents	 (Tavora,	 2014b).	 Several	




ie	 paracrine	 signals	 originating	 from	 endothelial	 cells	 that	 control	 the	
surrounding	malignant	cell	responses.	Although	the	endothelial	cell	specific	loss	
of	 FAK	 in	 tumour	 blood	 vessels	was	 not	 sufficient	 to	 affect	 baseline	 cytokine	




controlled	 by	 changes	 in	 NF-kB	 signaling,	 a	 known	 regulator	 of	 cytokine	
production	 (Funakoshi-Tago,	 2003;	 Zhang,	 2006;	 Petzold,	 2009;	 Tseng,	 2010;	
Ben-Neriah,	2011;	DiDonato,	2012;	Tavora,	2014b).	Although	of	great	 interest	
as	 a	possible	 regulator	of	 chemosensitisation	 in	 cancer	 therapy	 this	 study	did	
not	 address	 the	 roles	 of	 endothelial	 cell	 FAK-Y397	 and	 FAK-Y861	
phosphorylation	 in	 cytokine	 production.	 In	 my	 project	 I	 isolated	 endothelial	
cells	 from	Cre-neg	and	Cre-pos;	FAK-WTKI,	FAK-Y397FKI	and	FAK-Y861KI	mice.	





increase	 in	 CCL1	 and	 CCL2	 production.	 In	 contrast	 FAK-Y861F	 mutations	
induced	 much	 less	 of	 a	 change	 in	 CCL1	 but	 an	 increase	 in	 a	 several	 other	
cytokines	with	a	particularly	a	massive	(100	fold	or	more)	increase	in	IL-13,	IL-
1F3,	CCL4,	 IL-1F1	and	CCL2.	Why	 total	deletion	of	 endothelial-cell	FAK	would	
not	 affect	 cytokine	 production	 prior	 to	 treatment	with	DNA-damaging	 agents,	
but	 that	non-phosphorylation	mutations	of	FAK-Y397F	and	FAK-Y861F	should	
induce	 changes	 is	 still	 unclear	 and	might	 relate	 to	 changes	 in	 signalling	down	
stream	 of	 FAK-Y397F	 and	 FAK-Y861F	 that	 are	 not	 apparent	 in	 the	 FAK-null	
endothelial	 cells.	 It	 is	 of	 special	 interest	 that	 the	 FAK-Y861F	mutation	 should	
induce	such	a	dramatic	change	in	a	wide	range	of	cytokines	that	the	FAK-Y397F	
mutant	 does	 not.	 It	 is	 tempting	 to	 speculate	 that	 these	 data	 may	 relate	 to	
differential	 tumour	 growth	 and	 angiogenesis	 responses	 in	 the	 Cre-pos;	 FAK-
Y397FKI	and	Cre-pos;	FAK-Y861FKI	mice,	possibly	by	changing	immune	infiltrate	
responses	and	thus	dependence	on	endothelial	FAK	for	angiogenic	changes.	 In	
other	 words,	 could	 it	 be	 that	 the	 change	 in	 the	 cytokine	 profiles	 of	 these	
mutant	 forms	 of	 endothelial	 cells	 is	 able	 to	 compensate	 for	 the	 quantitative	
defect	 in	 blood	 vessel	 density	without	 affecting	 tumour	 growth?	 It	 should	 be	
noted	that	these	experiments	are	still	preliminary	and	that	further	repeats	and	
statistical	analysis	would	be	required	to	really	confirm	them.	Nevertheless	FAK-
KO	 endothelial	 cells	 where	 shown	 to	 have	 the	 expression	 of	 their	 cytokines	
modulated	 after	 exposure	 to	 doxorubicine	 and	 these	 cytokine	 variations	 have	
been	linked	to	NF-kB	signalling	(Tavora,	2014b).	Therefore	understanding	how	









angiogenic	responses	 in	vivo	 and	ex	vivo	 reveal	differential	 responses	 to	VEGF,	
PlGF,	 bFGF	 and	 Ang2	 stimulation	 depending	 on	 the	 FAK-Y397F	 or	 FAK-Y861	
mutations.	
Endothelial	cells	bearing	FAK-Y397F	or	FAK-Y861F	mutation	have	been	
isolated	 from	 the	mutated	mice	 and	 future	work,	 designed	 to	 understand	 the	
molecular	mechanisms	underlying	the	differential	phenotypes	observed	in	vivo,	
will	include	using	these	cells	to	confirm	the	cytokine	array	findings,	to	perform	
adhesion	 assays,	 growth	 factor	 induced	 migration	 assays,	 proliferation	 and	
apoptosis	assays.	Importantly	examining	integrin	expression	and	activity	as	well	
as	growth	factor	receptor	expression	levels	and	regulation	may	shed	light	on	the	
differential	 responses	 to	 the	 different	 growth	 factors	 and	 explain	 how	 these	
might	 relate	 back	 to	 angiogenesis	 control	 in	 vivo.	 Obviously	 determining	 the	
effect	of	Y397F	and	Y861F	mutations	on	downstream	signaling	such	as	ERK,	Akt	





not	 non-phosphorylatable	 forms	 of	 FAK-Y397	 and	 FAK-Y861	 can	 actually	







more	 opportunities	 for	 us	 to	 learn	 even	 more	 about	 how	 this	 non-receptor	










































Cre-neg;	 FAK-WTKI	 and	 Cre-pos;	 FAK-WTKI	 mice	 were	 given	 subcutaneous	 injections	 of	
syngeneic	B16F0	melanoma	cells,	5-7	days	after	tamoxifen	injection.	Tumour	dimensions	were	
measured	 from	 day	 6	 to	 day	 21	 and	 tumour	 volumes	 calculated	 (Volume	 =	 0.52	 x	 Length	 x	
Width2).	 At	 day	 21	 tumours	 were	 dissected.	 Statistical	 t-Student	 test	 was	 performed	 and	 no	
significant	difference	 in	 tumour	growth	was	determined	between	Cre-neg;	FAK-WTKI	and	Cre-






































































































































































B16F0	 tumour-burdened	 Cre-neg;	 FAK-Y397FKI	 and	 Cre-pos;	 FAK-Y397FKI	 were	 given	 intra-
peritoneal	 injections	 of	 Pimonidazole	 probe.	 FITC-anti-Pimonidazole	 antibody	 was	 used	 to	
detect	 hypoxic	 regions.	 The	 percentage	 of	 hypoxic	 area	 was	 determined	 by	 dividing	 the	
Pimonidazole	 stained	 area	 by	 the	 total	 field	 area.	 This	 data	 indicates	 that	 endothelial	 specific	

















































Cre-neg;	 FAK-Y861FKI	 and	 Cre-pos;	 FAK-Y861FKI	 mice	 were	 given	 subcutaneous	 injections	 of	
syngeneic	B16F0	melanoma	cells,	5-7	days	after	tamoxifen	injection.	Tumour	dimensions	were	
measured	 from	day	 11	 to	 day	 17	 and	 tumour	 volumes	 calculated	 (Volume	 =	 0.52	 x	 Length	 x	
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